<SEC-DOCUMENT>0000950170-24-018764.txt : 20240222
<SEC-HEADER>0000950170-24-018764.hdr.sgml : 20240222
<ACCEPTANCE-DATETIME>20240222161013
ACCESSION NUMBER:		0000950170-24-018764
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20240221
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240222
DATE AS OF CHANGE:		20240222

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Athira Pharma, Inc.
		CENTRAL INDEX KEY:			0001620463
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				453368487
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39503
		FILM NUMBER:		24664805

	BUSINESS ADDRESS:	
		STREET 1:		18706 NORTH CREEK PARKWAY, SUITE 104
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98011
		BUSINESS PHONE:		(425) 620-8501

	MAIL ADDRESS:	
		STREET 1:		18706 NORTH CREEK PARKWAY, SUITE 104
		CITY:			BOTHELL
		STATE:			WA
		ZIP:			98011

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	M3 Biotechnology, Inc.
		DATE OF NAME CHANGE:	20140924
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>atha-20240221.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:atha="http://athira.com/20240221" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_bc348e5a-23b4-4d14-9b18-3de0e63e34b1" name="dei:EntityCentralIndexKey" contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8">0001620463</ix:nonNumeric><ix:nonNumeric id="F_ed3073ed-fbb1-42ee-bd4b-1f7f0cf8a941" name="dei:AmendmentFlag" contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8" format="ixt:fixed-false">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="atha-20240221.xsd"/></ix:references><ix:resources><xbrli:context id="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001620463</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-21</xbrli:startDate><xbrli:endDate>2024-02-21</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div style="padding-top:0.5in;min-height:0.6in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:2pt;font-family:'Wingdings',serif;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="agm_results"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Washington, DC 20549</span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0e6af6f7-8ffc-479b-bea7-f0eef1916554" contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date of Report (Date of earliest event reported): </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a7c30f43-4619-42e9-98dd-89a1dbbf343e" contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">February 21, 2024</span></ix:nonNumeric></span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:8pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b33b3df9-7198-4601-ab97-50f613c3ea95" contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">Athira Pharma, Inc.</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:33.34%;"/>
    <td style="width:33.34%;"/>
    <td style="width:33.32%;"/>
   </tr>
   <tr style="height:13.7pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.042in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span><ix:nonNumeric id="F_97c6436e-8a3a-4135-b6f4-b86aae3b15a1" contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.042in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span><ix:nonNumeric id="F_84f450fb-b9c2-4d75-bb9e-1457628645e8" contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">001-39503</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.042in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span><ix:nonNumeric id="F_f76b8a7d-4972-4a36-a4a4-859d23773d7f" contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">45-3368487</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:20.15pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or other jurisdiction</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">of incorporation)</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Commission</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">File Number)</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;"><p style="font-size:8pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(IRS Employer</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:2pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identification No.)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_09782a93-8e97-44b6-9c54-38c667647ed3" contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">18706 North Creek Parkway</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b897400c-cdc8-41dd-8693-f74235025ba8" contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Suite 104</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"><br/></span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_95179633-6c7a-4313-94c6-dd380e78b6ce" contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Bothell</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_85772bb9-3352-4a1e-bfa8-fad543a4ad86" contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8" name="dei:EntityAddressStateOrProvince"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">WA</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0a1552fe-8eaf-418c-961a-2cd4cdf9b501" contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">98011</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Address of principal executive offices, including zip code)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(</span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2903e6a9-ba5a-47d8-b5d1-9fb82249ab36" contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">425</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">) </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0b77acdb-5c9a-4bec-87c6-94e511e42c56" contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">620-8501</span></ix:nonNumeric></span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Registrant&#8217;s telephone number, including area code)</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Former name or former address, if changed since last report)</span></p>
  <p style="margin-left:33.333%;padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.5pt solid;margin-right:33.333%;text-align:center;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:6pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:3.52%;"/>
    <td style="width:96.48%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_581b6222-14bc-448e-9a9b-88d29a4e0048" contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_4090156c-fe1b-4496-8ff4-bbf4ae9d768b" contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_347c9ccc-5e05-4c47-af51-3eaaf886afef" contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_6c81df5e-859f-4626-86fc-0f61386d7a0f" contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:35%;"/>
    <td style="width:30%;"/>
    <td style="width:35%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading Symbol(s)</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:9pt;white-space:pre-wrap;word-break:break-word;text-align:left;">
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.042in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_497fc471-dbad-493c-ba6d-f91278f30cc0" contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.042in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_9beb45f3-0f04-47d8-812b-9a825b3e6fb5" contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">ATHA</span></ix:nonNumeric></span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.042in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:9pt;"><ix:nonNumeric id="F_5469c7f0-cdc4-4da6-aae3-42818423cb87" contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;min-width:fit-content;">&#160;<br/>(The Nasdaq Global Select Market)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:6pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:25%;"/>
    <td style="width:75%;"/>
   </tr>
   <tr style="height:15.1pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Emerging Growth Company</span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span><ix:nonNumeric id="F_f7d1e54e-fa92-4213-bbaf-019470183ed0" contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act).  </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_65baee7c-e5f5-4ea0-8cbd-bd8332dc3918" contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="padding-bottom:1pt;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:2.25pt double;text-align:left;"><span style="white-space:pre-wrap;font-size:4pt;font-family:'Wingdings',serif;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.6in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.6in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2.02 Results of Operations and Financial Condition.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 22, 2024, Athira Pharma, Inc. (the &#8220;Company&#8221;) issued a press release reporting its financial results for the year ended December 31, 2023. A copy of the press release is furnished herewith as Exhibit 99.1.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Adoption of Inducement Plan</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On February 21, 2024, the Board adopted the Athira Pharma, Inc. 2024 Inducement Equity Incentive Plan (the &#8220;Inducement Plan&#8221;) and, subject to the adjustment provisions of the Inducement Plan, reserved 750,000 shares of the Company&#8217;s common stock for issuance pursuant to equity awards granted under the Inducement Plan.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Inducement Plan was adopted without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. The Inducement Plan provides for the grant of equity-based awards, including nonstatutory stock options, restricted stock units, restricted stock, stock appreciation rights, performance shares and performance units, and its terms are substantially similar to the Company&#8217;s 2020 Equity Incentive Plan, including with respect to treatment of equity awards in the event of a &#8220;merger&#8221; or &#8220;change in control&#8221; as defined under the Inducement Plan, but with such other terms and conditions intended to comply with the Nasdaq inducement award exception or to comply with the Nasdaq acquisition and merger exception. However, the Company&#8217;s 2020 Equity Incentive Plan permits certain exchange programs (including repricings) without stockholder approval, while the Inducement Plan does not allow exchange programs.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">In accordance with Rule 5635(c)(4) of the Nasdaq Listing Rules, awards under the Inducement Plan may only be made to individuals not previously employees or non-employee directors of the Company (or following such individuals&#8217; bona fide period of non-employment with the Company), as an inducement material to the individuals&#8217; entry into employment with the Company.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">A copy of the Inducement Plan and related form agreements under the Inducement Plan are attached as Exhibit 10.1 hereto and incorporated by reference herein. The above description of the Inducement Plan does not purport to be complete and is qualified in its entirety by reference to such exhibit.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">I</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">tem 7.01 Regulation FD Disclosure.</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company announces material information to the public through a variety of means, including filings with the Securities and Exchange Commission, press releases, public conference calls, the Company&#8217;s website (www.athira.com), its investor relations website (investors.athira.com), and its news site (investors.athira.com/news-and-events/press-releases). The Company uses these channels, as well as social media, including its X account (formerly known as Twitter)(@athirapharma), LinkedIn account (www.linkedin.com/company/athirapharma), Instagram account (@athirapharma) and Facebook page (www.facebook.com/athirapharmainc), to communicate with investors and the public about the Company, its product candidates, and other matters. Therefore, the Company encourages investors, the media, and others interested in the Company to review the information it makes public in these locations, as such information could be deemed to be material information.</span></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 9.01 Financial Statements and Exhibits.</span></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d) Exhibits.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:9%;"/>
    <td style="width:1%;"/>
    <td style="width:90%;"/>
   </tr>
   <tr style="height:8pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.042in;vertical-align:bottom;border-bottom:1pt solid;padding-right:0.028in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit No.</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;border-bottom:1pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;border-bottom:1pt solid;padding-right:0.028in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10.1</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="atha-ex10_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">2024 Inducement Equity Incentive Plan and related form agreements</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.028in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99.1</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><a href="atha-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Athira Pharma, Inc. press release dated February 22, 2024</span></a></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.028in;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:right;"><p style="font-size:6pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (formatted as Inline XBRL)</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information furnished in this Current Report under Items 2.02 and 7.01 and exhibit 99.1 attached hereto shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.6in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.6in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:2pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.6in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
  <div style="padding-top:0.5in;min-height:0.6in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:5%;"/>
    <td style="width:45%;"/>
    <td style="width:5%;"/>
    <td style="width:45%;"/>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.042in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Athira Pharma, Inc.</span></p></td>
   </tr>
   <tr style="white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="vertical-align:top;padding-right:0.042in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date:</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.042in;text-align:right;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">February 22, 2024</span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;border-bottom:1pt solid;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Mark Litton</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.042in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Mark Litton</span></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-left:0.042in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    <td style="padding-left:0.042in;vertical-align:bottom;padding-right:0.028in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.6in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <hr style="page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>atha-ex10_1.htm
<DESCRIPTION>EX-10.1
<TEXT>
<html>
 <head>
  <title>EX-10.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ATHIRA PHARMA, INC.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2024 INDUCEMENT EQUITY INCENTIVE PLAN</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Purposes of the Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The purposes of this Plan are to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals entering into employment with the Company or any Parent or Subsidiary of the Company.  </font></div></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Plan permits the grant of Nonstatutory Stock Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units and Performance Awards.  Each Award under the Plan is intended to qualify as an employment inducement award under Nasdaq Listing Rule 5635(c)(4), the official regulations and other official interpretive material and guidance issued under such rule (together, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Inducement Listing Rules</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Definitions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  As used herein, the following definitions will apply:</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Administrator</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Board or any of its Committees as will be administering the Plan, in accordance with Section 4 of the Plan.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Applicable Laws</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the legal and regulatory requirements relating to the administration of equity-based awards, including but not limited to the related issuance of shares of Common Stock, including but not limited to, under U.S. federal and state corporate laws, U.S. federal and state securities laws, the Code, any stock exchange or quotation system on which the Common Stock is listed or quoted and the applicable laws of any non-U.S. country or jurisdiction where Awards are, or will be, granted under the Plan.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Award</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, individually or collectively, a grant under the Plan of Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, or Performance Awards.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the written or electronic agreement setting forth the terms and provisions applicable to each Award granted under the Plan.  The Award Agreement is subject to the terms and conditions of the Plan.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Board</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Board of Directors of the Company.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the occurrence of any of the following events:</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Change in Ownership of the Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  A change in the ownership of the Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">which occurs on the date that any one person, or more than one person acting as a group (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Person</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), acquires ownership of the stock of the Company that, together with the stock held by such Person, constitutes more than fifty percent (50%) of the total voting power of the stock of the Company; provided, however, that for purposes of this subsection (a), the acquisition of additional stock by any one Person, who is considered to own more than fifty percent (50%) of the total voting power of the stock of the Company will not be considered a Change in Control; provided, further, that any change in the ownership of the stock of the Company as a result of a private financing of  the Company that is approved by the Board also will not be considered a Change in Control.  Further, if the stockholders of the Company immediately before such change in ownership continue to retain </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">immediately after the change in ownership, in substantially the same proportions as their ownership of shares of the Company&#x2019;s voting stock immediately prior to the change in ownership, direct or indirect beneficial ownership of fifty percent (50%) or more of the total voting power of the stock of the Company or of the ultimate parent entity of the Company, such event will not be considered a Change in Control under this subsection (a).  For this purpose, indirect beneficial ownership will include, without limitation, an interest resulting from ownership of the voting securities of one or more corporations or other business entities which own the Company, as the case may be, either directly or through one or more subsidiary corporations or other business entities; or</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Change in Effective Control of the Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  If the Company has a class of securities registered pursuant to Section 12 of the Exchange Act, a change in the effective control of the Company which occurs on the date that a majority of members of the Board is replaced during any twelve (12) month period by Directors whose appointment or election is not endorsed by a majority of the members of the Board prior to the date of the appointment or election.  For purposes of this subsection (b), if any Person is considered to be in effective control of the Company, the acquisition of additional control of the Company by the same Person will not be considered a Change in Control; or</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Change in Ownership of a Substantial Portion of the Company&#x2019;s Assets</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  A change in the ownership of a substantial portion of the Company&#x2019;s assets which occurs on the date that any Person acquires (or has acquired during the twelve (12) month period ending on the date of the most recent acquisition by such Person or Persons) assets from the Company that have a total gross fair market value equal to or more than fifty percent (50%) of the total gross fair market value of all of the assets of the Company immediately prior to such acquisition or acquisitions; provided, however, that for purposes of this subsection (c), the following will not constitute a change in the ownership of a substantial portion of the Company&#x2019;s assets: (i) a transfer to an entity that is controlled by the Company&#x2019;s stockholders immediately after the transfer, or (ii) a transfer of assets by the Company to: (A) a stockholder of the Company (immediately before the asset transfer) in exchange for or with respect to the Company&#x2019;s stock, (B) an entity, fifty percent (50%) or more of the total value or voting power of which is owned, directly or indirectly, by the Company, (C) a Person, that owns, directly or indirectly, fifty percent (50%) or more of the total value or voting power of all the outstanding stock of the Company, or (D) an entity, at least fifty percent (50%) of the total value or voting power of which is owned, directly or indirectly, by a Person described in this subsection (c)(ii)(C).  For purposes of this subsection (c), gross fair market value means the value of the assets of the Company, or the value of the assets being disposed of, determined without regard to any liabilities associated with such assets.</font></div></div>
  <p style="text-indent:20%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For purposes of this Section 2.6, persons will be considered to be acting as a group if they are owners of a corporation that enters into a merger, consolidation, purchase or acquisition of stock, or similar business transaction with the Company.</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding the foregoing, a transaction will not be deemed a Change in Control unless the transaction qualifies as a change in control event within the meaning of Code Section 409A.</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Further and for the avoidance of doubt, a transaction will not constitute a Change in Control if: (x) its primary purpose is to change the jurisdiction of the Company&#x2019;s</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">incorporation, or (y) its primary purpose is to create a holding company that will be owned in substantially the same proportions by the persons who held the Company&#x2019;s securities immediately before such transaction.</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Code</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the U.S. Internal Revenue Code of 1986, as amended.  Reference to a specific section of the Code or regulation thereunder will include such section or regulation, any valid regulation or other formal guidance of general or direct applicability promulgated under such section, and any comparable provision of any future legislation or regulation amending, supplementing or superseding such section or regulation.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Committee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a committee of Directors or of other individuals satisfying Applicable Laws appointed by the Board, or by a duly authorized committee of the Board,  in accordance with Section 4 hereof.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.9</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Common Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the common stock of the Company.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.10</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Athira Pharma, Inc., a</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Delaware corporation, or any successor thereto.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.11</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Consultant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any natural person, including an advisor, engaged by the Company or any of its Parent or Subsidiaries to render bona fide services to such entity, provided the services (a) are not in connection with the offer or sale of securities in a capital-raising transaction, and (b) do not directly promote or maintain a market for the Company&#x2019;s securities, in each case, within the meaning of Form S-8 promulgated under the Securities Act, and provided further, that a Consultant will include only those persons to whom the issuance of Shares may be registered under Form S-8 promulgated under the Securities Act.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.12</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Director</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a member of the Board.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.13</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Disability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means total and permanent disability as defined in Code Section 22(e)(3), provided that the Administrator in its discretion may determine whether a permanent and total disability exists in accordance with uniform and non-discriminatory standards adopted by the Administrator from time to time.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.14</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Employee</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means any person, including Officers and Directors, employed by the Company or any Parent or Subsidiary of the Company.  Neither service as a Director nor payment of a director&#x2019;s fee by the Company will be sufficient to constitute &#x201c;employment&#x201d; by the Company. However, for the avoidance of doubt, although a person who is an Employee also may be a Director, a person who already is serving as a Director prior to becoming an Employee will not be eligible to be granted an Award under the Plan unless permitted under the Inducement Listing Rules.  The Company shall determine in good faith and in the exercise of its discretion whether an individual has become or has ceased to be an Employee and the effective date of such individual&#x2019;s employment or termination of employment, as the case may be.  For purposes of an individual&#x2019;s rights, if any, under the Plan as of the time of the Company&#x2019;s determination, all such determinations by the Company shall be final, binding and conclusive, notwithstanding that the Company or any court of law or governmental agency subsequently makes a contrary determination.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.15</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exchange Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the U.S. Securities Exchange Act of 1934, as amended, including the rules and regulations promulgated thereunder.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.16</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exchange Program</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a program under which (a) outstanding Awards are surrendered or cancelled in exchange for awards of the same type (which may have higher or lower exercise prices and different terms), awards of a different type, and/or cash, (b) Participants would have the opportunity to transfer any outstanding Awards to a financial institution or other person or entity selected by the Administrator, and/or (c) the exercise price of an outstanding Award is reduced.  Pursuant to the provisions of Section 4.3, the Administrator may not institute an Exchange Program.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.17</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Fair Market Value</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means, as of any date and unless the Administrator determines otherwise, the value of Common Stock determined as follows:</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If the Common Stock is listed on any established stock exchange or a national market system, including without limitation the New York Stock Exchange or the Nasdaq Global Select Market, the Nasdaq Global Market, or the Nasdaq Capital Market of The Nasdaq Stock Market, its Fair Market Value will be the closing sales price for such stock (or, if no closing sales price was reported on that date, as applicable, on the last Trading Day such closing sales price was reported) as quoted on such exchange or system on the date of determination, as reported in </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Wall Street Journal</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> or such other source as the Administrator deems reliable;</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">If the Common Stock is regularly quoted by a recognized securities dealer but selling prices are not reported, the Fair Market Value of a Share will be the mean between the high bid and low asked prices for the Common Stock on the day of determination (or, if no bids and asks were reported on that date, as applicable, on the last Trading Day such bids and asks were reported), as reported in </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">The Wall Street Journal</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> or such other source as the Administrator deems reliable; or</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In the absence of an established market for the Common Stock, the Fair Market Value will be determined in good faith by the Administrator.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.18</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Fiscal Year</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the fiscal year of the Company.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.19</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Incentive Stock Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an Option that by its terms qualifies and is otherwise intended to qualify as an incentive stock option within the meaning of Code Section 422 and the regulations promulgated thereunder.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.20</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Nonstatutory Stock Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an Option that by its terms does not qualify or is not intended to qualify as an Incentive Stock Option.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.21</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Officer</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act and the rules and regulations promulgated thereunder. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.22</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a stock option granted pursuant to the Plan.  All Options granted under the Plan will be Nonstatutory Stock Options.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.23</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Parent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a &#x201c;parent corporation,&#x201d; whether now or hereafter existing, as defined in Code Section 424(e).</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.24</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Participant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the holder of an outstanding Award.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.25</font><div style="width:100%;display:inline;" id="ole_link4"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Performance Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; </font><font id="ole_link3"></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">means an Award which may be earned in whole or in part upon attainment of performance goals</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> or other vesting criteria as the Administrator may determine and which may be cash- or stock-denominated and may be settled for cash, Shares or other securities or a combination of the foregoing under Section 10.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.26</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Performance Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Performance Period as defined in Section 10.2.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.27</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Period of Restriction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the period (if any) during which the transfer of Shares of Restricted Stock are subject to restrictions and therefore, the Shares are subject to a substantial risk of forfeiture.  Such restrictions may be based on the passage of time, the achievement of target levels of performance, or the occurrence of other events as determined by the Administrator.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.28</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means this 2024 Inducement Equity Incentive Plan.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.29</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Restricted Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Shares issued pursuant to an Award of Restricted Stock under Section 8 of the Plan, or issued pursuant to the early exercise of an Option.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.30</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Restricted Stock Unit</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a bookkeeping entry representing an amount equal to the Fair Market Value of one Share, granted pursuant to Section 9.  Each Restricted Stock Unit represents an unfunded and unsecured obligation of the Company.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.31</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Rule 16b&#x2011;3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Rule 16b&#x2011;3 of the Exchange Act or any successor to Rule 16b&#x2011;3, as in effect when discretion is being exercised with respect to the Plan.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.32</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 16b</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Section 16(b) of the Exchange Act.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.33</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means Code Section 409A and the U.S. Treasury Regulations and guidance thereunder, and any applicable state law equivalent, as each may be promulgated, amended or modified from time to time.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.34</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Securities Act</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the U.S. Securities Act of 1933, as amended, including the rules and regulations promulgated thereunder. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.35</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Service Provider</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an Employee, Director or Consultant.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.36</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Share</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a share of the Common Stock, as adjusted in accordance with Section 15 of the Plan.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.37</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Stock Appreciation Right</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means an Award, granted alone or in connection with an Option, that pursuant to Section 7 is designated as a Stock Appreciation Right.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.38</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Subsidiary</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a &#x201c;subsidiary corporation,&#x201d; whether now or hereafter exist&#x1f;ing, as defined in Code Section 424(f).</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">5</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.39</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Trading Day</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means a day that the primary stock exchange, national market system, or other trading platform, as applicable, upon which the Common Stock is listed (or otherwise trades regularly, as determined by the Administrator, in its sole discretion) is open for trading.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.40</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">U.S. Treasury Regulations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; means the Treasury Regulations of the Code.  Reference to a specific Treasury Regulation or Section of the Code will include such Treasury Regulation or Section, any valid regulation promulgated under such Section, and any comparable provision of any future legislation or regulation amending, supplementing or superseding such Section or regulation. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Stock Subject to the Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Stock Subject to the Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Subject to adjustment upon changes in capitalization of the Company as provided in Section 14, the maximum aggregate number of Shares that may be subject to Awards and sold under the Plan is 750,000 Shares.  In addition, Shares may become available for issuance under Section 3.2.  The Shares may be authorized but unissued, or reacquired Common Stock.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Lapsed Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  If an Award expires or becomes unexercisable without having been exercised in full, or, with respect to Restricted Stock, Restricted Stock Units, Performance Units or Performance Shares is forfeited to or repurchased by the Company due to the failure to vest, the unpurchased Shares (or for Awards other than Options or Stock Appreciation Rights the forfeited or repurchased Shares) which were subject thereto will become available for future grant or sale under the Plan (unless the Plan has terminated).  With respect to Stock Appreciation Rights, only Shares actually issued pursuant to a Stock Appreciation Right will cease to be available under the Plan; all remaining Shares under Stock Appreciation Rights will remain available for future grant or sale under the Plan (unless the Plan has terminated).  Shares that have actually been issued under the Plan under any Award will not be returned to the Plan and will not become available for future distribution under the Plan; provided, however, that if Shares issued pursuant to Awards of Restricted Stock, Restricted Stock Units or Performance Awards are repurchased by the Company or are forfeited to the Company due to the failure to vest, such Shares will become available for future grant under the Plan.  Shares used to pay the exercise price of an Award or to satisfy the tax liabilities or withholdings related to an Award will become available for future grant or sale under the Plan.  To the extent an Award under the Plan is paid out in cash rather than Shares, such cash payment will not result in reducing the number of Shares available for issuance under the Plan.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Share Reserve</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company, during the term of this Plan, will at all times reserve and keep available such number of Shares as will be sufficient to satisfy the requirements of the Plan.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Administration of the Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Procedure</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.1.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Multiple Administrative Bodies</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Different Committees with respect to different groups of Service Providers may administer the Plan.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">6</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.1.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Rule 16b-3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  To the extent desirable to qualify transactions hereunder as exempt under Rule 16b-3, the transactions contemplated hereunder will be structured to satisfy the requirements for exemption under Rule 16b-3.</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.1.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Other Administration</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Other than as provided above, the Plan will be administered by (A) the Board or (B) a Committee, which Committee will be constituted to comply with Applicable Laws. Until and unless determined otherwise by the Board, the Compensation Committee of the Board will have full authority to act as Administrator.</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.1.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Approval</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Awards granted under the Plan must be approved by a majority of the Company&#x2019;s &#x201c;Independent Directors&#x201d; (within the meaning of the Inducement Listing Rules) or the Compensation Committee of the Board, in each case acting as the Administrator.</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.1.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Delegation of Authority for Day-to-Day Administration</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Except to the extent prohibited by Applicable Laws and except to the extent provided by subsection 4.1.4, the Administrator may delegate to one or more individuals the day-to-day administration of the Plan and any of the functions assigned to it in this Plan.  Such delegation may be revoked at any time.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Powers of the Administrator</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Subject to the provisions of the Plan, and in the case of a Committee, subject to the specific duties delegated by the Board to such Committee, the Administrator will have the authority, in its discretion:</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to determine the Fair Market Value;</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to select the individuals to whom Awards may be granted hereunder, subject to Section 5 (which Awards will be intended as a material inducement to the individual becoming an Employee);</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to determine the number of Shares to be covered by each Award granted hereunder;</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to approve forms of Award Agreements for use under the Plan;</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to determine the terms and conditions, not inconsistent with the terms of the Plan, of any Award granted hereunder.  Such terms and conditions include, but are not limited to, the exercise price, the time or times when Awards may be exercised (which may be based on performance criteria), any vesting acceleration or waiver of forfeiture restrictions, and any restriction or limitation regarding any Award or the Shares relating thereto (including but not limited to, temporarily suspending the exercisability of an Award if the Administrator deems such suspension to be necessary or appropriate for administrative purposes or to comply with Applicable Laws, provided that such suspension must be lifted prior to the expiration of the maximum term and post-termination exercisability period of an Award), based in each case on such factors as the Administrator will determine;</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to construe and interpret the terms of the Plan and Awards granted pursuant to the Plan; </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">7</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to prescribe, amend and rescind rules and regulations relating to the Plan, including rules and regulations relating to sub-plans established for the purpose of satisfying applicable non&#x2011;U.S. laws or for qualifying for favorable tax treatment under applicable non&#x2011;U.S. laws;</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to modify or amend each Award (subject to Section 19.3), including but not limited to the discretionary authority to extend the post-termination exercisability period of Awards and to extend the maximum term of an Option or Stock Appreciation Right (subject to Sections 6.3 and 7.5);</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to allow Participants to satisfy withholding tax obligations in a manner prescribed in Section 16;</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">(j)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to authorize any person to execute on behalf of the Company any instrument required to effect the grant of an Award previously granted by the Administrator;</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">(k)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to allow a Participant to defer the receipt of the payment of cash or the delivery of Shares that otherwise would be due to such Participant under an Award; and</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">(l)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">to make all other determinations deemed necessary or advisable for administering the Plan.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Exchange Program</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Notwithstanding anything herein to the contrary, the Administrator may not institute an Exchange Program.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Effect of Administrator&#x2019;s Decision</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Administrator&#x2019;s decisions, determinations and interpretations will be final and binding on all Participants and any other holders of Awards and will be given the maximum deference permitted by Applicable Laws.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Eligibility</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Nonstatutory Stock Options, Stock Appreciation Rights, Restricted Stock, Restricted Stock Units, Performance Shares and Performance Units may be granted to Employees, so long as the following requirements are satisfied:</font></div></div>
  <div style="text-indent:14.133%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:14.13%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.004%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Employee was not previously an Employee or Director, or the Employee is to become employed by the Company or any of its Parents or Subsidiaries following a bona fide period of non-employment (within the meaning of the Inducement Listing Rules); and </font></div></div>
  <div style="text-indent:14.133%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:14.13%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.004%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The grant of the Award or Awards is an inducement material to the Employee&#x2019;s entering into employment with the Company (or any of its Parents or Subsidiaries, as applicable) in accordance with the Inducement Listing Rules.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Stock Options</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Grant of Options</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Subject to the terms and provisions of the Plan, including without limitation the eligibility requirements of Section 5, the Administrator, at any time and from time to time, may grant Options to any individual as a material inducement to the individual becoming an Employee, which grant shall become effective only if the individual actually becomes an Employee, in such amounts as the Administrator, in its sole discretion, will determine.  </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Option Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Each Award of an Option will be evidenced by an Award Agreement that will specify the exercise price, the term of the Option, the number of Shares subject to the Option, the exercise restrictions, if any, applicable to the Option, and such other terms and conditions as the Administrator, in its sole discretion, will determine.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Term of Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The term of each Option will be stated in the Award Agreement; provided, however, that the term will be no more than ten (10) years from the date of grant thereof.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Option Exercise Price and Consideration</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.4.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exercise Price</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The per Share exercise price for the Shares to be issued pursuant to the exercise of an Option will be determined by the Administrator, but will be no less than one hundred percent (100%) of the Fair Market Value per Share on the date of grant.   </font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.4.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Waiting Period and Exercise Dates</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  At the time an Option is granted, the Administrator will fix the period within which the Option may be exercised and will determine any conditions that must be satisfied before the Option may be exercised.</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.4.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Form of Consideration</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Administrator will determine the acceptable form of consideration for exercising an Option, including the method of payment.  Such consideration may consist entirely of: (a) cash (including cash equivalents); (b) check; (c) promissory note, to the extent permitted by Applicable Laws, (d) other Shares, provided that such Shares have a Fair Market Value on the date of surrender equal to the aggregate exercise price of the Shares as to which such Option will be exercised and provided further that accepting such Shares will not result in any adverse accounting consequences to the Company, as the Administrator determines in its sole discretion; (e) consideration received by the Company under a cashless exercise program (whether through a broker or otherwise) implemented by the Company in connection with the Plan; (f) by net exercise; (g) such other consideration and method of payment for the issuance of Shares to the extent permitted by Applicable Laws, or (h) any combination of the foregoing methods of payment.  In making its determination as to the type of consideration to accept, the Administrator will consider if acceptance of such consideration may be reasonably expected to benefit the Company.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exercise of Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.5.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Procedure for Exercise; Rights as a Stockholder</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Any Option granted hereunder will be exercisable according to the terms of the Plan and at such times and under such conditions as determined by the Administrator and set forth in the Award Agreement.  An Option may not be exercised for a fraction of a Share.</font></div></div>
  <p style="text-indent:20%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">An Option will be deemed exercised when the Company receives: (a) notice of exercise (in such form as the Administrator may specify from time to time) from the person entitled to exercise the Option, and (b) full payment for the Shares with respect to which the Option is exercised (together with applicable tax withholding).  Full payment may consist of any consideration and method of payment authorized by the Administrator and permitted by the Award Agreement and the Plan.  Shares issued upon exercise of an Option will be issued in the name of the Participant or, if requested by the Participant, in the name of the Participant and his or her spouse.  Until the Shares are issued (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">of the Company), no right to vote or receive dividends or any other rights as a stockholder will exist with respect to the Shares subject to an Option, notwithstanding the exercise of the Option.  The Company will issue (or cause to be issued) such Shares promptly after the Option is exercised.  No adjustment will be made for a dividend or other right for which the record date is prior to the date the Shares are issued, except as provided in Section 14</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">of the Plan.</font></p>
  <p style="text-indent:20%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exercising an Option in any manner will decrease the number of Shares thereafter available, both for purposes of the Plan and for sale under the Option, by the number of Shares as to which the Option is exercised.</font></p>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.5.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Termination of Relationship as a Service Provider</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  If a Participant ceases to be a Service Provider, other than upon the Participant&#x2019;s termination as the result of the Participant&#x2019;s death or Disability, the Participant may exercise his or her Option, to the extent that the Option is vested on the date of termination, within ninety (90) days of termination, or such shorter or longer period of time, as is specified in the Award Agreement or in writing by the Administrator, in each case, in no event later than the expiration of the term of such Option as set forth in the Award Agreement.  Unless otherwise provided by the Administrator, if on the date of termination the Participant is not vested as to his or her entire Option, the Shares covered by the unvested portion of the Option will revert to the Plan.  If after termination the Participant does not exercise his or her Option within the time specified by the Administrator, the Option will terminate, and the Shares covered by such Option will revert to the Plan.</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.5.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Disability of Participant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  If a Participant ceases to be a Service Provider as a result of the Participant&#x2019;s Disability, the Participant may exercise his or her Option within six (6) months of termination, or such longer or shorter period of time as is specified in the Award Agreement or in writing by the Administrator (but in no event later than the expiration of the term of such Option as set forth in the Award Agreement) to the extent the Option is vested on the date of termination.  Unless otherwise provided by the Administrator, if on the date of termination the Participant is not vested as to his or her entire Option, the Shares covered by the unvested portion of the Option will revert to the Plan.  If after termination the Participant does not exercise his or her Option within the time specified herein, the Option will terminate, and the Shares covered by such Option will revert to the Plan.</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.5.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Death of Participant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  If a Participant dies while a Service Provider, the Option may be exercised within six (6) months following the Participant&#x2019;s death, or within such longer or shorter period of time as is specified in the Award Agreement or in writing by the Administrator (but in no event later than the expiration of the term of such Option as set forth in the Award Agreement) to the extent that the Option is vested on the date of death, by the Participant&#x2019;s designated beneficiary, provided such beneficiary has been designated prior to the Participant&#x2019;s death in a form (if any) acceptable to the Administrator.  If no such beneficiary has been designated by the Participant, then such Option may be exercised by the personal representative of the Participant&#x2019;s estate or by the person(s) to whom the Option is transferred pursuant to the Participant&#x2019;s will or in accordance with the laws of descent and distribution (each, a &#x201c;Legal Representative&#x201d;).  If the Option is exercised pursuant to this Section 6.5.4, Participant&#x2019;s designated beneficiary or Legal Representative shall be subject to the terms of this Plan and the Award Agreement, including but not limited to the restrictions on transferability and forfeitability applicable to the Service Provider.  Unless otherwise provided by the Administrator, if at the time of death Participant is not vested as to his or her entire Option, the </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">10</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Shares covered by the unvested portion of the Option will immediately revert to the Plan.  If the Option is not so exercised within the time specified herein, the Option will terminate, and the Shares covered by such Option will revert to the Plan.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.5.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tolling Expiration</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  A Participant&#x2019;s Award Agreement may also provide that:</font></div></div>
  <div style="text-indent:26.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:26.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.067%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">if the exercise of the Option following the cessation of Participant&#x2019;s status as a Service Provider (other than upon the Participant&#x2019;s death or Disability) would result in liability under Section 16(b), then the Option will terminate on the earlier of (i) the expiration of the term of the Option set forth in the Award Agreement, or (ii) the tenth (10</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">) day after the last date on which such exercise would result in liability under Section 16(b); or</font></div></div>
  <div style="text-indent:26.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:26.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:5.067%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">if the exercise of the Option following the cessation of the Participant&#x2019;s status as a Service Provider (other than upon the Participant&#x2019;s death or Disability) would be prohibited at any time solely because the issuance of Shares would violate the registration requirements under the Securities Act, then the Option will terminate on the earlier of (i) the expiration of the term of the Option or (ii) the expiration of a period of thirty (30) days after the cessation of the Participant&#x2019;s status as a Service Provider during which the exercise of the Option would not be in violation of such registration requirements.   </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Stock Appreciation Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Grant of Stock Appreciation Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Subject to the terms and provisions of the Plan, including without limitation the eligibility requirements of Section 5, a Stock Appreciation Right may be granted to any individual as a material inducement to the individual becoming an Employee, which grant shall become effective only if the individual actually becomes an Employee, at any time and from time to time as will be determined by the Administrator, in its sole discretion.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Number of Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Administrator will have complete discretion to determine the number of Shares subject to any Award of Stock Appreciation Rights.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exercise Price and Other Terms</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The per Share exercise price for the Shares that will determine the amount of the payment to be received upon exercise of a Stock Appreciation Right as set forth in Section 7.6 will be determined by the Administrator and will be no less than one hundred percent (100%) of the Fair Market Value per Share on the date of grant.  Otherwise, the Administrator, subject to the provisions of the Plan, will have complete discretion to determine the terms and conditions of Stock Appreciation Rights granted under the Plan.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Stock Appreciation Right Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Each Stock Appreciation Right grant will be evidenced by an Award Agreement that will specify the exercise price, the term of the Stock Appreciation Right, the conditions of exercise, and such other terms and conditions as the Administrator, in its sole discretion, will determine.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Expiration of Stock Appreciation Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  A Stock Appreciation Right granted under the Plan will expire upon the date determined by the Administrator, in its sole discretion, and set forth in the Award Agreement.  Notwithstanding the foregoing, the rules of Section 6.4 relating to the maximum term and Section 6.3 relating to exercise also will apply to Stock Appreciation Rights.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">11</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Payment of Stock Appreciation Right Amount</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Upon exercise of a Stock Appreciation Right, a Participant will be entitled to receive payment from the Company in an amount determined by multiplying:</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The difference between the Fair Market Value of a Share on the date of exercise over the exercise price; times</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The number of Shares with respect to which the Stock Appreciation Right is exercised.</font></div></div>
  <p style="text-indent:20%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">At the discretion of the Administrator, the payment upon Stock Appreciation Right exercise may be in cash, in Shares of equivalent value, or in some combination thereof.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Restricted Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Grant of Restricted Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Subject to the terms and provisions of the Plan, including without limitation the eligibility requirements of Section 5, the Administrator, at any time and from time to time, may grant Shares of Restricted Stock to any individual as a material inducement to the individual becoming an Employee, which grant shall become effective only if the individual actually becomes an Employee, in such amounts as the Administrator, in its sole discretion, will determine.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Restricted Stock Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Each Award of Restricted Stock will be evidenced by an Award Agreement that will specify the Period of Restriction (if any), the number of Shares granted, and such other terms and conditions as the Administrator, in its sole discretion, will determine.  Unless the Administrator determines otherwise, the Company as escrow agent will hold Shares of Restricted Stock until the restrictions on such Shares have lapsed.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Transferability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Except as provided in this Section 8 or as the Administrator determines, Shares of Restricted Stock may not be sold, transferred, pledged, assigned, or otherwise alienated or hypothecated until the end of the applicable Period of Restriction.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Other Restrictions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Administrator, in its sole discretion, may impose such other restrictions on Shares of Restricted Stock as it may deem advisable or appropriate.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Removal of Restrictions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Except as otherwise provided in this Section 8, Shares of Restricted Stock covered by each Restricted Stock grant made under the Plan will be released from escrow as soon as practicable after the last day of the Period of Restriction or at such other time as the Administrator may determine.  The Administrator, in its discretion, may accelerate the time at which any restrictions will lapse or be removed.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Voting Rights</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  During the Period of Restriction, Service Providers holding Shares of Restricted Stock granted hereunder may exercise full voting rights with respect to those Shares, unless the Administrator determines otherwise.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.7</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Dividends and Other Distributions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  During the Period of Restriction, Service Providers holding Shares of Restricted Stock will be entitled to receive all dividends and other distributions paid with respect to such Shares, unless the Administrator provides otherwise.  If any </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">12</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">such dividends or distributions are paid in Shares, the Shares will be subject to the same restrictions on transferability and forfeitability as the Shares of Restricted Stock with respect to which they were paid.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.8</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Return of Restricted Stock to Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  On the date set forth in the Award Agreement, the Restricted Stock for which restrictions have not lapsed will revert to the Company and again will become available for grant under the Plan.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Restricted Stock Units</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Grant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Subject to the terms and provisions of the Plan, including without limitation the eligibility requirements of Section 5, Restricted Stock Units may be granted at any time and from time to time as determined by the Administrator to any individual as a material inducement to the individual becoming an Employee, which grant shall become effective only if the individual actually becomes an Employee, in such amounts as the Administrator, in its sole discretion, will determine.  After the Administrator determines that it will grant Restricted Stock Units, it will advise the Participant in an Award Agreement of the terms, conditions, and restrictions related to the grant, including the number of Restricted Stock Units.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Vesting Criteria and Other Terms</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Administrator will set vesting criteria in its discretion, which, depending on the extent to which the criteria are met, will determine the number of Restricted Stock Units that will be paid out to the Participant.  The Administrator may set vesting criteria based upon the achievement of Company-wide, divisional, business unit, or individual goals (including, but not limited to, continued employment or service), applicable federal or state securities laws or any other basis determined by the Administrator in its discretion.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Earning Restricted Stock Units</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Upon meeting the applicable vesting criteria, the Participant will be entitled to receive a payout as determined by the Administrator.  Notwithstanding the foregoing, at any time after the grant of Restricted Stock Units, the Administrator, in its sole discretion, may reduce or waive any vesting criteria that must be met to receive a payout.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Form and Timing of Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Payment of earned Restricted Stock Units will be made at the time(s) determined by the Administrator and set forth in the Award Agreement.  The Administrator, in its sole discretion, may settle earned Restricted Stock Units in cash, Shares, or a combination of both.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Cancellation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  On the date set forth in the Award Agreement, all unearned Restricted Stock Units will be forfeited to the Company.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Performance Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Grant of Performance Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Subject to the terms and provisions of the Plan, including without limitation the eligibility requirements of Section 5, Performance Awards may be granted to any individual as a material inducement to the individual becoming an Employee, which grant shall become effective only if the individual actually becomes an Employee, at any time and from time to time, as will be determined by the Administrator, in its sole discretion.  </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">13</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Each Performance Award will be evidenced by an Award Agreement that will specify any time period during which any performance objectives or other vesting provisions will be measured (&#x201c;Performance Period&#x201d;), and such other terms and conditions as the Administrator determines.  Each Performance Award will have an initial value that is determined by the Administrator on or before its date of grant. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Objectives or Vesting Provisions and Other Terms. </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Administrator will set any objectives or vesting provisions that, depending on the extent to which any such objectives or vesting provisions are met, will determine the value of the payout for the Performance Awards. The Administrator may set vesting criteria based upon the achievement of Company-wide, divisional, business unit, or individual goals (including, but not limited to, continued employment or service), applicable federal or state securities laws, or any other basis determined by the Administrator in its discretion.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.4</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Earning Performance Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. After an applicable Performance Period has ended, the holder of a Performance Award will be entitled to receive a payout for the Performance Award earned by the Participant over the Performance Period. The Administrator, in its discretion,  may reduce or waive any performance objectives or other vesting provisions for such Performance Award.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.5</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Form and Timing of Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. Payment of earned Performance Awards will be made at the time(s) determined by the Administrator and set forth in the Award Agreement. The Administrator, in its sole discretion, may settle earned Performance Awards in cash, Shares, or a combination of both.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.6</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Cancellation of Performance Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. On the date set forth in the Award Agreement, all unearned or unvested Performance Awards will be forfeited to the Company, and again will be available for grant under the Plan.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Compliance With Section 409A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Awards will be designed and operated in such a manner that they are either exempt from the application of, or comply with, the requirements of Section 409A such that the grant, payment, settlement or deferral will not be subject to the additional tax or interest applicable under Section 409A, except as otherwise determined in the sole discretion of the Administrator.  The Plan and each Award Agreement under the Plan is intended to be exempt from or meet the requirements of Section 409A and will be construed and interpreted in accordance with such intent (including with respect to any ambiguities or ambiguous terms), except as otherwise determined in the sole discretion of the Administrator.  To the extent that an Award or payment, or the settlement or deferral thereof, is subject to Section 409A the Award will be granted, paid, settled or deferred in a manner that will meet the requirements of Section 409A, such that the grant, payment, settlement or deferral will not be subject to the additional tax or interest applicable under Section 409A. In no event will the Company or any of its Parent or Subsidiaries have any responsibility, liability, or obligation to reimburse, indemnify, or hold harmless a Participant (or any other person) in respect of Awards, for any taxes, penalties or interest that may be imposed on, or other costs incurred by, Participant (or any other person) as a result of Section 409A.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'PMingLiU',serif;min-width:fit-content;">  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">12.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Leaves of Absence/Transfer Between Locations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Unless the Administrator provides otherwise or as otherwise required by Applicable Laws, vesting of Awards granted hereunder will be </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">14</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">suspended during any unpaid leave of absence.  A Participant will not cease to be an Employee in the case of (a) any leave of absence approved by the Company or (b) transfers between locations of the Company or between the Company, its Parent, or any of its Subsidiaries.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">13.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Limited Transferability of Awards</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Unless determined otherwise by the Administrator (and subject to the provisions of Section 4.3), Awards may not be sold, pledged, assigned, hypothecated, transferred, or disposed of in any manner other than by will or by the laws of descent and distribution (which, for purposes of clarification, shall be deemed to include through a beneficiary designation if available in accordance with Section 6.5), and may be exercised, during the lifetime of the Participant, only by the Participant.  If the Administrator makes an Award transferable, such Award will contain such additional terms and conditions as the Administrator deems appropriate.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">14.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Adjustments; Dissolution or Liquidation; Merger or Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">14.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Adjustments</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  In the event that any dividend or other distribution (whether in the form of cash, Shares, other securities, or other property), recapitalization, stock split, reverse stock split, reorganization, merger, consolidation, split-up, spin-off, combination, reclassification, repurchase, or exchange of Shares or other securities of the Company, or other change in the corporate structure of the Company affecting the Shares occurs (other than any ordinary dividends or other ordinary distributions), the Administrator, in order to prevent diminution or enlargement of the benefits or potential benefits intended to be made available under the Plan, will adjust the number and class of shares of stock that may be delivered under the Plan and/or the number, class, and price of shares of stock covered by each outstanding Award, and numerical Share limits in Section 3.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">14.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Dissolution or Liquidation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  In the event of the proposed dissolution or liquidation of the Company, the Administrator will notify each Participant as soon as practicable prior to the effective date of such proposed transaction.  To the extent it has not been previously exercised, an Award will terminate immediately prior to the consummation of such proposed action.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">14.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Merger or Change in Control</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  In the event of a merger of the Company with or into another corporation or other entity or a Change in Control, each outstanding Award will be treated as the Administrator determines (subject to the provisions of the following paragraph) without a Participant&#x2019;s consent, including, without limitation, that (a) Awards will be assumed, or substantially equivalent awards will be substituted, by the acquiring or succeeding corporation (or an affiliate thereof) with appropriate adjustments as to the number and kind of shares and prices; (b) upon written notice to a Participant, that the Participant&#x2019;s Awards will terminate upon or immediately prior to the consummation of such merger or Change in Control; (c) outstanding Awards will vest and become exercisable, realizable, or payable, or restrictions applicable to an Award will lapse, in whole or in part prior to or upon consummation of such merger or Change in Control, and, to the extent the Administrator determines, terminate upon or immediately prior to the effectiveness of such merger or Change in Control; (d) (i) the termination of an Award in exchange for an amount of cash and/or property, if any, equal to the amount that would have been attained upon the exercise of such Award or realization of the Participant&#x2019;s rights as of the date of the occurrence of the transaction (and, for the avoidance of doubt, if as of the date of the occurrence of the transaction the Administrator determines in good faith that no amount would have been attained upon the exercise of such Award or realization of the Participant&#x2019;s rights, then such Award may be terminated by the Company without payment), or (ii) the replacement of such Award with other rights or property selected by the Administrator in its </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">15</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">sole discretion; or (e) any combination of the foregoing.  In taking any of the actions permitted under this Section 14.3, the Administrator will not be obligated to treat all Awards, all Awards held by a Participant, all Awards of the same type, or all portions of Awards, similarly.</font></div></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In the event that the successor corporation does not assume or substitute for the Award (or portion thereof), the Participant will fully vest in and have the right to exercise his or her outstanding Options and Stock Appreciation Rights (or portions thereof) not assumed or substituted for, including Shares as to which such Awards would not otherwise be vested or exercisable, all restrictions on Restricted Stock, Restricted Stock Units, Performance Shares and Performance Units (or portions thereof) not assumed or substituted for will lapse, and, with respect to Awards with performance-based vesting (or portions thereof) not assumed or substituted for, all performance goals or other vesting criteria will be deemed achieved at one hundred percent (100%) of target levels and all other terms and conditions met, in each case, unless specifically provided otherwise under the applicable Award Agreement or other written agreement between the Participant and the Company or any of its Subsidiaries or Parents, as applicable.  In addition, unless specifically provided otherwise under the applicable Award Agreement or other written agreement between the Participant and the Company or any of its Subsidiaries or Parents, as applicable, if an Option or Stock Appreciation Right (or portion thereof) is not assumed or substituted in the event of a merger or Change in Control, the Administrator will notify the Participant in writing or electronically that the Option or Stock Appreciation Right (or its applicable portion) will be exercisable for a period of time determined by the Administrator in its sole discretion, and the Option or Stock Appreciation Right (or its applicable portion) will terminate upon the expiration of such period.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For the purposes of this Section 14.3, an Award will be considered assumed if, following the merger or Change in Control, the Award confers the right to purchase or receive, for each Share subject to the Award immediately prior to the merger or Change in Control, the consideration (whether stock, cash, or other securities or property) received in the merger or Change in Control by holders of Common Stock for each Share held on the effective date of the transaction (and if holders were offered a choice of consideration, the type of consideration chosen by the holders of a majority of the outstanding Shares); provided, however, that if such consideration received in the merger or Change in Control is not solely common stock of the successor corporation or its Parent, the Administrator may, with the consent of the successor corporation, provide for the consideration to be received upon the exercise of an Option or Stock Appreciation Right or upon the payout of a Restricted Stock Unit, Performance Unit or Performance Share, for each Share subject to such Award, to be solely common stock of the successor corporation or its Parent equal in fair market value to the per share consideration received by holders of Common Stock in the merger or Change in Control.</font></p>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding anything in this Section 14.3 to the contrary, an Award that vests, is earned or paid-out upon the satisfaction of one or more performance goals will not be considered assumed if the Company or its successor modifies any of such performance goals without the Participant&#x2019;s consent, in all cases, unless specifically provided otherwise under the applicable Award Agreement or other written agreement between the Participant and the Company or any of its Subsidiaries or Parents, as applicable; provided, however, a modification to such performance goals only to reflect the successor corporation&#x2019;s post-Change in Control corporate structure will not be deemed to invalidate an otherwise valid Award assumption.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">16</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notwithstanding anything in this Section 14.3 to the contrary, and unless otherwise provided in an Award Agreement, if an Award that vests, is earned or paid-out under an Award Agreement is subject to Section 409A and if the change in control definition contained in the Award Agreement (or other agreement related to the Award, as applicable) does not comply with the definition of &#x201c;change in control&#x201d; for purposes of a distribution under Section 409A, then any payment of an amount that is otherwise accelerated under this Section will be delayed until the earliest time that such payment would be permissible under Section 409A without triggering any penalties applicable under Section 409A.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">15.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tax Withholding</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">15.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Withholding Requirements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Prior to the delivery of any Shares or cash pursuant to an Award (or exercise thereof) or such earlier time as any tax withholdings are due, the Company (or any of its Parent, Subsidiaries, or affiliates employing or retaining the services of a Participant, as applicable) will have the power and the right to deduct or withhold, or require a Participant to remit to the Company (or any of its Parent, Subsidiaries, or affiliates, as applicable)</font><font style="color:#1f3864;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">or a relevant tax authority, an amount sufficient to satisfy U.S. federal, state, local, non&#x2011;U.S., and other taxes (including the Participant&#x2019;s FICA obligation) required to be withheld or paid with respect to such Award (or exercise thereof).  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">15.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Withholding Arrangements</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Administrator, in its sole discretion and pursuant to such procedures as it may specify from time to time, may permit a Participant to satisfy such tax liability or withholding obligation, in whole or in part by such methods as the Administrator shall determine, including, without limitation, (a) paying cash, (b) electing to have the Company withhold otherwise deliverable cash or Shares having a fair market value equal to the minimum statutory amount required to be withheld or such greater amount as the Administrator may determine if such amount would not have adverse accounting consequences, as the Administrator determines in its sole discretion, (c) delivering to the Company already-owned Shares having a fair market value equal to the statutory amount required to be withheld or such greater amount as the Administrator may determine, in each case, provided the delivery of such Shares will not result in any adverse accounting consequences, as the Administrator determines in its sole discretion, (d) selling a sufficient number of Shares otherwise deliverable to the Participant through such means as the Administrator may determine in its sole discretion (whether through a broker or otherwise) equal to the amount required to be withheld</font><font style="color:#1f3864;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">or paid, (e) such other consideration and method of payment for the meeting of tax liabilities or withholding obligations as the Administrator may determine to the extent permitted by Applicable Laws, or (f) any combination of the foregoing methods of payment.  The amount of the withholding requirement will be deemed to include any amount which the Administrator agrees may be withheld at the time the election is made, not to exceed the amount determined by using the maximum federal, state or local marginal income tax rates applicable to the Participant with respect to the Award on the date that the amount of tax to be withheld is to be determined or such greater amount as the Administrator may determine if such amount would not have adverse accounting consequences, as the Administrator determines in its sole discretion.  The fair market value of the Shares to be withheld or delivered will be determined as of the date that the taxes are required to be withheld.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">16.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Effect on Employment or Service</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Neither the Plan nor any Award will confer upon a Participant any right with respect to continuing the Participant&#x2019;s relationship as a Service Provider </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">17</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">with the Company or its Subsidiaries or Parents, as applicable, nor will they interfere in any way with the Participant&#x2019;s right or the right of the Company and its Subsidiaries or Parents, as applicable, to terminate such relationship at any time, with or without cause, to the extent permitted by Applicable Laws.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">17.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Date of Grant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The date of grant of an Award will be, for all purposes, the date on which the Administrator makes the determination granting such Award, or such other later date as is determined by the Administrator.  Notice of the determination will be provided to each Participant within a reasonable time after the date of such grant.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">18.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Term of Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Plan will become effective upon its adoption by the Board or the designated Committee (as applicable).  It will continue in effect for a term of ten (10) years from the date of the initial action by the Board or its designated Committee (as applicable) to adopt the Plan unless terminated earlier under Section 19 of the Plan.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">19.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Amendment and Termination of the Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">19.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Amendment and Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Administrator may at any time amend, alter, suspend or terminate the Plan.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">19.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Stockholder Approval</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company will obtain stockholder approval of any Plan amendment to the extent that the Administrator (in its discretion) determines such approval is necessary and desirable to comply with Applicable Laws. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">19.3</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Effect of Amendment or Termination</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  No amendment, alteration, suspension or termination of the Plan will materially impair the rights of any Participant, unless mutually agreed otherwise between the Participant and the Administrator, which agreement must be in writing and signed by the Participant and the Company.  Termination of the Plan will not affect the Administrator&#x2019;s ability to exercise the powers granted to it hereunder with respect to Awards granted under the Plan prior to the date of such termination.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">20.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Conditions Upon Issuance of Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">20.1</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Legal Compliance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Shares will not be issued pursuant to the exercise of an Award unless the exercise of such Award and the issuance and delivery of such Shares will comply with Applicable Laws and will be further subject to the approval of counsel for the Company with respect to such compliance.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">20.2</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Investment Representations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  As a condition to the exercise of an Award, the Company may require the person exercising such Award to represent and warrant at the time of any such exercise that the Shares are being purchased only for investment and without any present intention to sell or distribute such Shares if, in the opinion of counsel for the Company, such a representation is required.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">21.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Inability to Obtain Authority</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The inability of the Company to obtain authority from any regulatory body having jurisdiction or to complete or comply with the requirements of any registration or other qualification of the Shares under any U.S. state or federal law or non&#x2011;U.S. law or under the rules and regulations of the Securities and Exchange Commission, the stock exchange on </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">18</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">which Shares of the same class are then listed, or any other governmental or regulatory body, which authority, registration, qualification or rule compliance is deemed by the Company&#x2019;s counsel to be necessary or advisable for the issuance and sale of any Shares hereunder, will relieve the Company of any liability in respect of the failure to issue or sell such Shares as to which such requisite authority, registration, qualification or rule compliance will not have been obtained.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">   </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">22.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Forfeiture Events</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Administrator may specify in an Award Agreement that the Participant&#x2019;s rights, payments, and benefits with respect to an Award will be subject to the reduction, cancellation, forfeiture, recoupment, reimbursement, or reacquisition upon the occurrence of certain specified events, in addition to any otherwise applicable vesting or performance conditions of an Award.  Notwithstanding any provisions to the contrary under this Plan, an Award shall be subject to the Company&#x2019;s clawback policy as may be established and/or amended from time to time to comply with Applicable Laws (including without limitation pursuant to the listing standards of any national securities exchange or association on which the Company&#x2019;s securities are listed or as may be required by the Dodd&#x2011;Frank Wall Street Reform and Consumer Protection Act) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Clawback Policy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  The Administrator may require a Participant to forfeit, return or reimburse the Company all or a portion of the Award and any amounts paid thereunder pursuant to the terms of the Clawback Policy or as necessary or appropriate to comply with Applicable Laws.  Unless this Section 22 specifically is mentioned and waived in an Award Agreement or other document, no recovery of compensation under a Clawback Policy or otherwise will constitute an event that triggers or contributes to any right of a Participant to resign for &#x201c;good reason&#x201d; or &#x201c;constructive termination&#x201d; (or similar term) under any agreement with the Company or any Parent or Subsidiary of the Company.</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">*          *          *</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">19</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ATHIRA PHARMA, INC.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2024 INDUCEMENT EQUITY INCENTIVE PLAN</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">STOCK OPTION AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">NOTICE OF STOCK OPTION GRANT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Unless otherwise defined herein, the terms defined in the Athira Pharma, Inc. 2024 Inducement Equity Incentive Plan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) shall have the same defined meanings in this Stock Option Agreement, which includes the Notice of Stock Option Grant (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notice of Grant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the Terms and Conditions of Stock Option Grant, attached hereto as </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the Exercise Notice, attached hereto as </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, and all other exhibits, appendices, and addenda attached hereto (together, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Option Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Participant Name:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Address:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The undersigned Participant has been granted an Option to purchase Common Stock of the Company, subject to the terms and conditions of the Plan and this Option Agreement, as follows:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Grant Number:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Date of Grant:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Vesting Commencement Date:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exercise Price per Share:	$</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Total Number of Shares Granted:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Total Exercise Price:	$</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Type of Option:	___ Incentive Stock Option</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	___ Nonstatutory Stock Option</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Term/Expiration Date:	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Vesting Schedule</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Subject to any acceleration provisions contained in the Plan, this Option Agreement or any other written agreement between Participant and the Company (or any Parent or Subsidiary of the Company, as applicable) governing the terms of this Option, this Option shall vest and be exercisable, in whole or in part, according to the following vesting schedule:</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[Insert Vesting Schedule]</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Termination Period</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Option shall be exercisable, to the extent vested, for three (3) months after Participant ceases to be a Service Provider, unless (x) such cessation is due to Participant&#x2019;s Disability, in which case this Option shall be exercisable, to the extent vested, for twelve (12) months after Participant ceases to be a Service Provider, or (y) such cessation is due to Participant&#x2019;s death or Participant dies within three (3) months following such date of cessation, in which case this Option shall be exercisable, to the extent vested, for eighteen (18) months after Participant ceases to be a Service Provider.  Notwithstanding the foregoing sentence, in no event may this Option be exercised after the Term/Expiration Date as provided above and this Option may be subject to earlier termination as provided in Section 14 of the Plan.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By Participant&#x2019;s signature and the signature of the representative of the Company below, Participant and the Company agree that this Option is granted under and governed by the terms and conditions of the Plan and this Option Agreement, including the Terms and Conditions of Stock Option Grant, attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, the Exercise Notice, attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, and all other exhibits, appendices and addenda attached hereto, all of which are made a part of this document.  Participant acknowledges receipt of a copy of the Plan.  Participant has reviewed the Plan and this Option Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Option Agreement and fully understands all provisions of the Plan and the Option Agreement.  Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions relating to the Plan or this Option Agreement.  Participant further agrees to notify the Company upon any change in Participant&#x2019;s residence address indicated below.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">PARTICIPANT</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">		</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ATHIRA PHARMA, INC.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">		</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">		</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Signature		Signature</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">		</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">		</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Print Name		Print Name</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">			</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">		</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">			Title</font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Residence Address:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">		</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">		</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 10.1</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT A</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ATHIRA PHARMA, INC.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2024 INDUCEMENT EQUITY INCENTIVE PLAN</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">STOCK OPTION AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">TERMS AND CONDITIONS OF STOCK OPTION GRANT</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">1.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Grant of Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The Company hereby grants to the individual (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Participant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) named in the Notice of Stock Option Grant of this Option Agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notice of Grant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), an option (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) to purchase the number of Shares set forth in the Notice of Grant, at the exercise price per Share set forth in the Notice of Grant (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exercise Price</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), subject to all of the terms and conditions in this Option Agreement and the Plan, which is incorporated herein by reference.  Subject to Section 19 of the Plan, in the event of a conflict between the terms and conditions of the Plan and this Option Agreement, the terms and conditions of the Plan shall prevail.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For U.S. taxpayers, if designated in the Notice of Grant as an Incentive Stock Option (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ISO</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), this Option is intended to qualify as an Incentive Stock Option as defined in Section 422 of the Code.  Nevertheless, to the extent that it exceeds the $100,000 rule of Code Section 422(d), this Option shall be treated as a Nonstatutory Stock Option (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">NSO</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  Further, if for any reason this Option (or portion thereof) shall not qualify as an ISO, then, to the extent of such nonqualification, such Option (or portion thereof) shall be regarded as a NSO granted under the Plan.  In no event shall the Administrator, the Company or any Parent or Subsidiary or any of their respective employees or directors have any liability to Participant (or any other person) due to the failure of the Option to qualify for any reason as an ISO.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For non-U.S. taxpayers, the Option will be designated as an NSO. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Vesting Schedule</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Except as provided in Section 3, the Option awarded by this Option Agreement will vest in accordance with the vesting provisions set forth in the Notice of Grant.  Unless specifically provided otherwise in this Option Agreement or other written agreement between Participant and the Company or any Parent or Subsidiary of the Company, as applicable, Shares subject to this Option that are scheduled to vest on a certain date or upon the occurrence of a certain condition will not vest in accordance with any of the provisions of this Option Agreement, unless Participant will have been continuously a Service Provider from the Date of Grant until the date such vesting occurs.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Administrator Discretion</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Administrator, in its discretion, may accelerate the vesting of the balance, or some lesser portion of the balance, of the unvested Option at any time, subject to the terms of the Plan.  If so accelerated, such Option will be considered as having vested as of the date specified by the Administrator.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exercise of Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Right to Exercise</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  This Option shall be exercisable during its term in accordance with the Vesting Schedule set out in the Notice of Grant and with the applicable provisions of the Plan and this Option Agreement.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Method of Exercise</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  This Option shall be exercisable by delivery of an exercise notice (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exercise Notice</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) in the form attached as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit B</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> to the Notice of Grant or in a manner and pursuant to such procedures as the Administrator may determine, which shall state the election to exercise the Option, the number of Shares with respect to which the Option is being exercised (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exercised Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), and such other representations and agreements as may be required by the Company.  The Exercise Notice shall be completed by Participant and delivered to the Company, accompanied by payment of the aggregate Exercise Price as to all Exercised Shares, together with any applicable Tax Obligations (as defined below).  This Option shall be deemed to be exercised upon receipt by the Company of such fully executed Exercise Notice accompanied by the aggregate Exercise Price, together with any applicable Tax Obligations.</font></div></div>
  <p style="text-indent:13.333%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Shares shall be issued pursuant to the exercise of an Option unless such issuance and such exercise comply with Applicable Laws.  Assuming such compliance, for income tax purposes the Shares shall be considered transferred to Participant on the date on which the Option is exercised with respect to such Shares.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Method of Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Payment of the aggregate Exercise Price shall be by any of the following, or a combination thereof, at the election of Participant:</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">cash; </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">check;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">consideration received by the Company under a formal cashless exercise program adopted by the Company in connection with the Plan; or </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">if Participant is a U.S. employee, surrender of other Shares which (i) shall be valued at its fair market value on the date of surrender, and (ii) must be owned free and clear of any liens, claims, encumbrances or security interests, if accepting such Shares, in the sole discretion of the Administrator, shall not result in any adverse accounting consequences to the Company.</font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">A non-U.S. resident&#x2019;s methods of exercise may be restricted by the terms and conditions of any appendix to this Agreement for Participant&#x2019;s country (including the Country Addendum, as defined below).</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Non-Transferability of Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  This Option may not be transferred in any manner otherwise than by will or by the laws of descent or distribution and may be exercised during the lifetime of Participant only by Participant.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Term of Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  This Option may be exercised only within the term set out in the Notice of Grant, and may be exercised during such term only in accordance with the Plan and the terms of this Option Agreement.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tax Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Responsibility for Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Participant acknowledges that, regardless of any action taken by the Company or, if different, Participant&#x2019;s employer or any Parent or Subsidiary to which Participant is providing services (together, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Service Recipients</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the ultimate liability for any tax and/or social insurance liability obligations and requirements in connection with the Option, including, without limitation, (i) all federal, state, and local taxes (including Participant&#x2019;s Federal Insurance Contributions Act (FICA) obligations) that are required to be withheld by any Service Recipient or other payment of tax-related items related to Participant&#x2019;s participation in the Plan and legally applicable to Participant, (ii) Participant&#x2019;s and, to the extent required by any Service Recipient, the Service Recipient&#x2019;s fringe benefit tax liability, if any, associated with the grant, vesting, or exercise of the Option or sale of Shares, and (iii) any other Service Recipient taxes the responsibility for which Participant has, or has agreed to bear, with respect to the Option (or exercise thereof or issuance of Shares thereunder) (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tax Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), is and remains Participant&#x2019;s sole responsibility and may exceed the amount actually withheld by the applicable Service Recipient(s).  Participant further acknowledges that no Service Recipient (A) makes any representations or undertakings regarding the treatment of any Tax Obligations in connection with any aspect of the Option, including, but not limited to, the grant, vesting or exercise of the Option, the subsequent sale of Shares acquired pursuant to such exercise and the receipt of any dividends or other distributions, and (B) makes any commitment to and is under any obligation to structure the terms of the grant or any aspect of the Option to reduce or eliminate Participant&#x2019;s liability for Tax Obligations or achieve any particular tax result.  Further, if Participant is subject to Tax Obligations in more than one jurisdiction between the Date of Grant and the date of any relevant taxable or tax withholding event, as applicable, Participant acknowledges that the applicable Service Recipient(s) (or former employer, as applicable) may be required to withhold or account for Tax Obligations in more than one jurisdiction.  If Participant fails to make satisfactory arrangements for the payment of any required Tax Obligations hereunder at the time of the applicable taxable event, Participant acknowledges and agrees that the Company may refuse to issue or deliver the Shares.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tax Withholding</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Pursuant to such procedures as the Administrator may specify from time to time, the applicable Service Recipient(s) will withhold the amount required to be withheld for the payment of Tax Obligations.  The Administrator, in its sole discretion and pursuant to such procedures as it may specify from time to time, may permit Participant to satisfy such Tax Obligations, in whole or in part (without limitation), if permissible by applicable local law, by (i) paying cash, (ii) electing to have the Company withhold otherwise deliverable Shares having a fair market value equal to the minimum amount that is necessary to meet the withholding requirement for such Tax Obligations (or such greater amount as Participant may elect if permitted by the Administrator, if such greater amount would not result in adverse financial accounting consequences), (iii) having the amount of such Tax Obligations withheld from Participant&#x2019;s wages or other cash compensation paid to Participant by the applicable Service Recipient(s), (iv) delivering to the Company Shares that Participant owns and that have vested with a fair market value equal to such Tax Obligations, or (v) selling a sufficient number of such Shares otherwise deliverable to Participant through such means as the Company may determine in its sole discretion (whether through a broker or otherwise) equal to the minimum amount that is necessary to meet the withholding requirement for such Tax Obligations (or such greater amount as Participant may elect if permitted by the Administrator, if such greater amount would not result in adverse financial accounting consequences).  To the extent determined appropriate by the Administrator in its discretion, the Administrator will </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">have the right (but not the obligation) to satisfy any Tax Obligations by reducing the number of Shares otherwise deliverable to Participant.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notice of Disqualifying Disposition of ISO Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  If the Option granted to Participant herein is an ISO, and if Participant sells or otherwise disposes of any of the Shares acquired pursuant to the ISO on or before the later of (i) the date two (2) years after the Date of Grant, or (ii) the date one (1) year after the date of exercise, Participant shall immediately notify the Company in writing of such disposition.  Participant agrees that Participant may be subject to income tax withholding by the Company on the compensation income recognized by Participant. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 409A.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  Under Section 409A, a stock right (such as the Option) that vests after December 31, 2004 (or that vested on or prior to such date but which was materially modified after October 3, 2004), that was granted with a per share exercise price that is determined by the Internal Revenue Service (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">IRS</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) to be less than the fair market value of an underlying share on the date of grant (a &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">discount option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) may be considered &#x201c;deferred compensation.&#x201d;  A stock right that is a &#x201c;discount option&#x201d; may result in (i) income recognition by the recipient of the stock right prior to the exercise of the stock right, (ii) an additional twenty percent (20%) federal income tax, and (iii) potential penalty and interest charges.  The &#x201c;discount option&#x201d; may also result in additional state income, penalty and interest tax to the recipient of the stock right.  Participant acknowledges that the Company cannot and has not guaranteed that the IRS will agree that the per Share exercise price of this Option equals or exceeds the fair market value of a Share on the date of grant in a later examination.  Participant agrees that if the IRS determines that the Option was granted with a per Share exercise price that was less than the fair market value of a Share on the date of grant, Participant shall be solely responsible for Participant&#x2019;s costs related to such a determination.  In no event will the Company or any of its Parent or Subsidiaries have any responsibility, liability, or obligation to reimburse, indemnify, or hold harmless Participant (or any other person) in respect of this Option or any other Awards, for any taxes, penalties or interest that may be imposed on, or other costs incurred by, Participant (or any other person) as a result of Section 409A. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Rights as Stockholder</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Neither Participant nor any person claiming under or through Participant will have any of the rights or privileges of a stockholder of the Company in respect of any Shares deliverable hereunder unless and until certificates representing such Shares (which may be in book entry form) will have been issued, recorded on the records of the Company or its transfer agents or registrars, and delivered to Participant (including through electronic delivery to a brokerage account).  After such issuance, recordation and delivery, Participant will have all the rights of a stockholder of the Company with respect to voting such Shares and receipt of dividends and distributions on such Shares.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">10.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Entire Agreement; Governing Law</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Plan is incorporated herein by reference.  The Plan and this Option Agreement constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof, and may not be modified adversely to Participant&#x2019;s interest except by means of a writing signed by the Company and Participant.  This Option Agreement is governed by the internal substantive laws but not the choice of law rules of the State of Delaware.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">11.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Guarantee of Continued Service</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  PARTICIPANT ACKNOWLEDGES AND AGREES THAT THE VESTING OF SHARES PURSUANT TO THE VESTING SCHEDULE HEREOF IS EARNED ONLY BY CONTINUING AS A SERVICE PROVIDER, WHICH UNLESS PROVIDED OTHERWISE UNDER APPLICABLE LAWS IS AT THE WILL OF THE COMPANY (OR THE PARENT OR SUBSIDIARY EMPLOYING OR RETAINING PARTICIPANT) AND NOT THROUGH THE ACT OF BEING HIRED, BEING GRANTED THIS OPTION OR ACQUIRING SHARES HEREUNDER. PARTICIPANT FURTHER ACKNOWLEDGES AND AGREES THAT THIS OPTION AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS A SERVICE PROVIDER FOR THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND SHALL NOT INTERFERE IN ANY WAY WITH PARTICIPANT&#x2019;S RIGHT OR THE RIGHT OF THE COMPANY (OR THE PARENT OR SUBSIDIARY EMPLOYING OR RETAINING PARTICIPANT) TO TERMINATE PARTICIPANT&#x2019;S RELATIONSHIP AS A SERVICE PROVIDER, SUBJECT TO APPLICABLE LAW, WHICH TERMINATION, UNLESS PROVIDED OTHERWISE UNDER APPLICABLE LAW, MAY BE AT ANY TIME, WITH OR WITHOUT CAUSE.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">12.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Nature of Grant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  In accepting the Option, Participant acknowledges, understands and agrees that:</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(a)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the grant of the Option is voluntary and occasional and does not create any contractual or other right to receive future grants of options, or benefits in lieu of options, even if options have been granted in the past; </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(b)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">all decisions with respect to future option or other grants, if any, will be at the sole discretion of the Administrator; </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(c)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Participant is voluntarily participating in the Plan; </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(d)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the Option and any Shares acquired under the Plan are not intended to replace any pension rights or compensation;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(e)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the Option and Shares acquired under the Plan and the income and value of same, are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments; </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(f)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the future value of the Shares underlying the Option is unknown, indeterminable, and cannot be predicted with certainty; </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(g)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">if the underlying Shares do not increase in value, the Option will have no value; </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(h)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">if Participant exercises the Option and acquires Shares, the value of such Shares may increase or decrease in value, even below the Exercise Price;</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">for purposes of the Option, Participant&#x2019;s status as a Service Provider will be considered terminated as of the date Participant is no longer actively providing services to the </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">5</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company or any Parent or Subsidiary (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is a Service Provider or the terms of Participant&#x2019;s employment or service agreement, if any), and unless otherwise expressly provided in this Option Agreement (including by reference in the Notice of Grant to other arrangements or contracts) or determined by the Administrator, (i) Participant&#x2019;s right to vest in the Option under the Plan, if any, will terminate as of such date and will not be extended by any notice period (e.g., Participant&#x2019;s period of service would not include any contractual notice period or any period of &#x201c;garden leave&#x201d; or similar period mandated under employment laws in the jurisdiction where Participant is a Service Provider or the terms of Participant&#x2019;s employment or service agreement, if any, unless Participant is providing bona fide services during such time); and (ii) the period (if any) during which Participant may exercise the Option after such termination of Participant&#x2019;s engagement as a Service Provider will commence on the date Participant ceases to actively provide services and will not be extended by any notice period mandated under employment laws in the jurisdiction where Participant is employed or terms of Participant&#x2019;s engagement agreement, if any; the Administrator shall have the exclusive discretion to determine when Participant is no longer actively providing services for purposes of this Option grant (including whether Participant may still be considered to be providing services while on a leave of absence and consistent with local law);</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(j)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">unless otherwise provided in the Plan or by the Administrator in its discretion, the Option and the benefits evidenced by this Option Agreement do not create any entitlement to have the Option or any such benefits transferred to, or assumed by, another company nor be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares; and</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:13.333%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.8%;text-indent:0;display:inline-flex;justify-content:flex-start;">(k)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the following provisions apply only if Participant is providing services outside the United States:</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">(i)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the Option and the Shares subject to the Option are not part of normal or expected compensation or salary for any purpose; </font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">(ii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Participant acknowledges and agrees that no Service Recipient shall be liable for any foreign exchange rate fluctuation between Participant&#x2019;s local currency and the United States Dollar that may affect the value of the Option or of any amounts due to Participant pursuant to the exercise of the Option or the subsequent sale of any Shares acquired upon exercise; and</font></div></div>
  <div style="text-indent:20%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:20%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.667%;text-indent:0;display:inline-flex;justify-content:flex-start;">(iii)</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">no claim or entitlement to compensation or damages shall arise from forfeiture of the Option resulting from the termination of Participant&#x2019;s status as a Service Provider (for any reason whatsoever, whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is a Service Provider or the terms of Participant&#x2019;s employment or service agreement, if any), and in consideration of the grant of the Option to which Participant is otherwise not entitled, Participant irrevocably agrees never to institute any claim against any Service Recipient, waives his or her ability, if any, to bring any such claim, and releases each Service Recipient from any such claim; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, Participant shall be deemed irrevocably to have agreed not to pursue such claim and agrees to execute any and all documents necessary to request dismissal or withdrawal of such claim.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">6</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">13.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Advice Regarding Grant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding Participant&#x2019;s participation in the Plan, or Participant&#x2019;s acquisition or sale of the Shares underlying the Option.  Participant is hereby advised to consult with his or her own personal tax, legal and financial advisers regarding his or her participation in the Plan before taking any action related to the Plan.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">14.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Data Privacy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of Participant&#x2019;s personal data as described in this Option Agreement and any other Option grant materials by and among, as applicable, the Service Recipients for the exclusive purpose of implementing, administering and managing Participant&#x2019;s participation in the Plan.  </font></div></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Participant understands that the Company and the Service Recipient may hold certain personal information about Participant, including, but not limited to, Participant&#x2019;s name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any Shares or directorships held in the Company, details of all Options or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in Participant&#x2019;s favor (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Data</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201d;), for the exclusive purpose of implementing, administering and managing the Plan.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">   </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Participant understands that Data may be transferred to a stock plan service provider, as may be selected by the Company in the future, assisting the Company with the implementation, administration and management of the Plan.  Participant understands that the recipients of the Data may be located in the United States or elsewhere, and that the recipients&#x2019; country of operation (e.g., the United States) may have different data privacy laws and protections than Participant&#x2019;s country.  Participant understands that if he or she resides outside the United States, he or she may request a list with the names and addresses of any potential recipients of the Data by contacting his or her local human resources representative.  Participant authorizes the Company, any stock plan service provider selected by the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing his or her participation in the Plan.  Participant understands that Data will be held only as long as is necessary to implement, administer and manage Participant&#x2019;s participation in the Plan.  Participant understands if he or she resides outside the United States, he or she may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing his or her local human resources representative.  Further, Participant understands that he or she is providing the consents herein on a purely voluntary basis.  If Participant does not consent, or if Participant later seeks to revoke his or her consent, his or her status as a Service Provider and career with the Service Recipient will not be adversely affected.  The only adverse consequence of refusing or withdrawing Participant&#x2019;s consent is that the Company would not be able to grant Participant Options or other equity awards or administer or maintain such awards.  Therefore, Participant understands that refusing or withdrawing his or her consent may affect Participant&#x2019;s ability to participate in the Plan.  For more information on the consequences of Participant&#x2019;s refusal to consent or withdrawal of consent, Participant understands that he or she may contact his or her local human resources representative.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">7</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">15.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Address for Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Any notice to be given to the Company under the terms of this Option Agreement will be addressed to the Company at Athira Pharma, Inc., 400 Mason Rd., Suite 300, Seattle, Washington 98195-2141, or at such other address as the Company may hereafter designate in writing. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">16.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Successors and Assigns</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company may assign any of its rights under this Option Agreement to single or multiple assignees, and this Option Agreement shall inure to the benefit of the successors and assigns of the Company.  Subject to the restriction on transfer herein set forth, this Option Agreement shall be binding upon the executors, administrators, heirs, successors and assigns of Participant.  The rights and obligations of Participant under this Option Agreement may be assigned only with the prior written consent of the Company. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">17.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Additional Conditions to Issuance of Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  If at any time the Company will determine, in its discretion, that the listing, registration, qualification or rule compliance of the Shares upon any securities exchange or under any state, federal or non-U.S. law, the tax code and related regulations or under the rulings or regulations of the U.S. Securities and Exchange Commission or any other governmental regulatory body or the clearance, consent or approval of the U.S. Securities and Exchange Commission or any other governmental regulatory authority is necessary or desirable as a condition to the exercise of the Options or the purchase by, or issuance of Shares, to Participant (or his or her estate) hereunder, such exercise, purchase or issuance will not occur unless and until such listing, registration, qualification, rule compliance, clearance, consent or approval will have been completed, effected or obtained free of any conditions not acceptable to the Company.  Subject to the terms of the Option Agreement and the Plan, the Company will not be required to issue any certificate or certificates for (or make any entry on the books of the Company or of a duly authorized transfer agent of the Company of) the Shares hereunder prior to the lapse of such reasonable period of time following the date of exercise of the Option as the Administrator may establish from time to time for reasons of administrative convenience.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">18.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Language</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  If Participant has received this Option Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">19.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Interpretation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Administrator will have the power to interpret the Plan and this Option Agreement and to adopt such rules for the administration, interpretation and application of the Plan as are consistent therewith and to interpret or revoke any such rules (including, but not limited to, the determination of whether or not any Shares subject to the Option have vested).  All actions taken and all interpretations and determinations made by the Administrator in good faith will be final and binding upon Participant, the Company and all other interested persons.  Neither the Administrator nor any person acting on behalf of the Administrator will be personally liable for any action, determination or interpretation made in good faith with respect to the Plan or this Option Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">20.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Electronic Delivery and Acceptance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company may, in its sole discretion, decide to deliver any documents related to the Option awarded under the Plan or future options that may be awarded under the Plan by electronic means or require Participant to participate in the Plan by electronic means.  Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through any on-line or electronic system established and maintained by the Company or a third party designated by the Company.</font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">21.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Captions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Captions provided herein are for convenience only and are not to serve as a basis for interpretation or construction of this Option Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">22.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Option Agreement Severable</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  In the event that any provision in this Option Agreement will be held invalid or unenforceable, such provision will be severable from, and such invalidity or unenforceability will not be construed to have any effect on, the remaining provisions of this Option Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">23.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Amendment, Suspension or Termination of the Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  By accepting this Option, Participant expressly warrants that he or she has received an Option under the Plan, and has received, read and understood a description of the Plan.  Participant understands that the Plan is discretionary in nature and may be amended, suspended or terminated by the Administrator at any time.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">24.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Country Addendum</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Notwithstanding any provisions in this Option Agreement, this Option shall be subject to any special terms and conditions set forth in an appendix (if any) to this Option Agreement for any country whose laws are applicable to Participant and this Option (as determined by the Administrator in its sole discretion) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Country Addendum</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  Moreover, if Participant relocates to one of the countries included in the Country Addendum (if any), the special terms and conditions for such country will apply to Participant, to the extent the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons.  The Country Addendum (if any) constitutes a part of this Option Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">25.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Modifications to the Option Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  This Option Agreement constitutes the entire understanding of the parties on the subjects covered.  Participant expressly warrants that he or she is not accepting this Option Agreement in reliance on any promises, representations, or inducements other than those contained herein.  Modifications to this Option Agreement or the Plan can be made only in an express written contract executed by a duly authorized officer of the Company.  Notwithstanding anything to the contrary in the Plan or this Option Agreement, the Company reserves the right to revise this Option Agreement as it deems necessary or advisable, in its sole discretion and without the consent of Participant, to comply with Code Section 409A or to otherwise avoid imposition of any additional tax or income recognition under Section 409A of the Code in connection with the Option.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">26.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Waiver</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Either party&#x2019;s failure to enforce any provision or provisions of this Option Agreement shall not in any way be construed as a waiver of any such provision or provisions, nor prevent that party from thereafter enforcing each and every other provision of this Option Agreement.  The rights granted both parties herein are cumulative and shall not constitute a waiver of either party&#x2019;s right to assert all other legal remedies available to it under the circumstances.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">27.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tax Consequences</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Participant has reviewed with his or her own tax advisers the U.S. federal, state, local and non-U.S. tax consequences of this investment and the transactions contemplated by this Option Agreement.  With respect to such matters, Participant relies solely on such advisers and not on any statements or representations of the Company or any of its agents, written or oral.  Participant understands that Participant (and not the Company) shall be responsible for Participant&#x2019;s own tax liability that may arise as a result of this investment or the transactions contemplated by this Option Agreement.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">*          *          *</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT B</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ATHIRA PHARMA, INC.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2024 INDUCEMENT EQUITY INCENTIVE PLAN</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">STOCK OPTION AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXERCISE NOTICE</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Athira Pharma, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[		]</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Attention: [Finance Department]</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">2.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exercise of Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Effective as of today, ________________, ____, the undersigned (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Participant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) hereby elects to exercise Participant&#x2019;s option (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Option</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) to purchase ________________ shares of the Common Stock (the &#x201c;Shares&#x201d;) of Athira Pharma, Inc. (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) under and pursuant to the 2024 Inducement Equity Incentive Plan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and the Stock Option Agreement dated ______________, _____, including the Notice of Stock Option Grant, and the Terms and Conditions of Stock Option Grant attached as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> thereto and other exhibits, appendices and addenda attached thereto (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Option Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  Unless otherwise defined herein, capitalized terms used in this Exercise Notice will be ascribed the same defined meanings as set forth in the Option Agreement (or the Plan or other written agreement as specified in the Option Agreement). </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">3.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Delivery of Payment</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Participant herewith delivers to the Company the full purchase price of the Shares, as set forth in the Option Agreement, and any Tax Obligations to be paid in connection with the exercise of the Option.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">4.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Representations of Participant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Participant acknowledges that Participant has received, read and understood the Plan and the Option Agreement and agrees to abide by and be bound by their terms and conditions.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">5.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Rights as Stockholder</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Until the issuance of the Shares (as evidenced by the appropriate entry on the books of the Company or of a duly authorized transfer agent of the Company), no right to vote or receive dividends or any other rights as a stockholder shall exist with respect to the Common Stock subject to the Option, notwithstanding the exercise of the Option.  The Shares so acquired shall be issued to Participant as soon as practicable after the Option is exercised in accordance with the Option Agreement.  No adjustment shall be made for a dividend or other right for which the record date is prior to the date of issuance except as provided in Section 14 of the Plan.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">6.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tax Consultation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Participant understands that Participant may suffer adverse tax consequences as a result of Participant&#x2019;s purchase or disposition of the Shares.  Participant represents that Participant has consulted with any tax consultants Participant deems advisable in connection with </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div style="font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the purchase or disposition of the Shares and that Participant is not relying on the Company for any tax advice.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">7.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Interpretation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Any dispute regarding the interpretation of this Exercise Notice shall be submitted by Participant or by the Company forthwith to the Administrator, which shall review such dispute at its next regular meeting.  The resolution of such a dispute by the Administrator shall be final and binding on all parties to the maximum extent permitted by law.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">8.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Governing Law; Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  This Exercise Notice is governed by the internal substantive laws, but not the choice of law rules, of Delaware.  In the event that any provision hereof becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Exercise Notice shall continue in full force and effect.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12pt;justify-content:flex-start;margin-bottom:0;min-width:6.667%;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:2.4%;text-indent:0;display:inline-flex;justify-content:flex-start;">9.</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Entire Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Plan and Option Agreement are incorporated herein by reference.  The Plan and the Option Agreement (including this Exercise Notice and any exhibits, appendices, and addenda attached to the Notice of Stock Option Grant of the Option Agreement) constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof, and may not be modified adversely to Participant&#x2019;s interest except by means of a writing signed by the Company and Participant.</font></div></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Submitted by:		Accepted by:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">PARTICIPANT</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">		</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ATHIRA PHARMA, INC.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">		</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">		</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Signature		By</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">		</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">		</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br></font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Print Name		Print Name</font></p>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">			</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">		</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">			Title</font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Address:		Address:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">		</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">		</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br>		</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">		<br></font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">			</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">		</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">			</font><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Date Received</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">APPENDIX A</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ATHIRA PHARMA, INC.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2024 INDUCEMENT EQUITY INCENTIVE PLAN</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">COUNTRY ADDENDUM TO STOCK OPTION AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Unless otherwise defined herein, capitalized terms used in this Country Addendum to Stock Option Agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Country Addendum</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) will be ascribed the same defined meanings as set forth in the Option Agreement of which this Country Addendum forms a part (or the Plan or other written agreement as specified in the Option Agreement).</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Terms and Conditions</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Country Addendum includes additional terms and conditions that govern this Option awarded to Participant under the Plan if he or she resides and/or works in one of the countries listed below.  If Participant is a citizen or resident (or is considered as such for local law purposes) of a country other than the country in which Participant is currently residing and/or working, or if Participant relocates to another country after the Options is granted, the Company, in its discretion, shall determine to what extent the terms and conditions contained herein shall apply to Participant.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Notifications</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Country Addendum also may include information regarding exchange controls and certain other issues of which Participant should be aware with respect to participation in the Plan.  The information is based on the securities, exchange control, and other Applicable Laws in effect in the respective countries as of ______, 202_.  Such Applicable Laws often are complex and change frequently.  As a result, the Company strongly recommends that Participant not rely on the information in this Country Addendum as the only source of information relating to the consequences of Participant&#x2019;s participation in the Plan because the information may be out of date at the time Participant vests in or exercises the Option or sells Shares acquired under the Plan.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In addition, the information contained in this Country Addendum is general in nature and may not apply to Participant&#x2019;s particular situation, and the Company is not in a position to assure Participant of a particular result.  Participant should seek appropriate professional advice as to how the Applicable Laws in Participant&#x2019;s country may apply to his or her situation.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Finally, if Participant is a citizen or resident of a country other than the one in which Participant currently is residing and/or working, transfers residence and/or employment to another country after this Option is awarded, or is considered a resident of another country for local law purposes, the information in this Country Addendum may not apply to Participant in the same manner.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ATHIRA PHARMA, INC.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2024 INDUCEMENT EQUITY INCENTIVE PLAN</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">RESTRICTED STOCK UNIT AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">NOTICE OF RESTRICTED STOCK UNIT GRANT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Unless otherwise defined herein, the terms defined in the Athira Pharma, Inc. 2024 Inducement Equity Incentive Plan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) will have the same defined meanings in this Restricted Stock Unit Agreement which includes the Notice of Restricted Stock Unit Grant (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notice of Grant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the Terms and Conditions of Restricted Stock Unit Grant, attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, and all other exhibits, appendices, and addenda attached hereto (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-55.556%;padding-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:12pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Participant Name:	</font></p>
  <p style="margin-left:6.667%;text-indent:-55.556%;padding-left:33.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Address:	</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The undersigned Participant has been granted an Award of Restricted Stock Units, subject to the terms and conditions of the Plan and this Award Agreement, as follows:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Grant Number:				______________________________</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Date of Grant:					______________________________</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Vesting Commencement Date:		______________________________</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Total Number of Restricted Stock Units:	______________________________</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Vesting Schedule</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For purposes of this Agreement, &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Quarterly Vesting Dates</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d; with respect to any calendar year means [Month Day], [Month Day], [Month Day], and [Month Day], provided, to the extent any of such dates occurs on a weekend day or U.S. federal holiday, the Quarterly Vesting Date will be deemed to occur instead on the immediately following day that is not a weekend day or U.S. federal holiday.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Subject to any acceleration provisions contained in the Plan, this Award Agreement or any other written agreement between Participant and the Company (or any Parent or Subsidiary of the Company, as applicable) governing the terms of this Award, the Restricted Stock Units will be scheduled to vest according to the following vesting schedule:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">[Insert Vesting Schedule]</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">By Participant&#x2019;s signature and the signature of the representative of the Company below, Participant and the Company agree that this Award of Restricted Stock Units is granted under and governed by the terms and conditions of the Plan and this Award Agreement, including the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Terms and Conditions of Restricted Stock Unit Grant, attached hereto as </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Exhibit A</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, and all other exhibits, appendices and addenda attached hereto, all of which are made a part of this document.  Participant acknowledges receipt of a copy of the Plan.  Participant has reviewed the Plan and this Award Agreement in their entirety, has had an opportunity to obtain the advice of counsel prior to executing this Award Agreement and fully understands all provisions of the Plan and this Award Agreement.  Participant hereby agrees to accept as binding, conclusive and final all decisions or interpretations of the Administrator upon any questions relating to the Plan or this Award Agreement.  Participant further agrees to notify the Company upon any change in Participant&#x2019;s residence address indicated below.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">PARTICIPANT		ATHIRA PHARMA, INC.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">		</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Signature		Signature</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">		</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Print Name		Print Name</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">			</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">			Title</font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Residence Address:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">		</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">		</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">- </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> -</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EXHIBIT A</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ATHIRA PHARMA, INC.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2024 INDUCEMENT EQUITY INCENTIVE PLAN</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">RESTRICTED STOCK UNIT AGREEMENT</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">TERMS AND CONDITIONS OF RESTRICTED STOCK UNIT GRANT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Grant of Restricted Stock Units</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company hereby grants to the individual (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Participant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) named in the Notice of Restricted Stock Unit Grant of this Award Agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Notice of Grant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) under the Plan an Award of Restricted Stock Units, and subject to the terms and conditions of this Award Agreement and the Plan, which is incorporated herein by reference.  Subject to Section 19 of the Plan, in the event of a conflict between the terms and conditions of the Plan and this Award Agreement, the terms and conditions of the Plan shall prevail.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company&#x2019;s Obligation to Pay</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Each Restricted Stock Unit represents the right to receive a Share on the date it vests.  Unless and until the Restricted Stock Units will have vested in the manner set forth in Section 3 or 4, Participant will have no right to payment of any such Restricted Stock Units.  Prior to actual payment of any vested Restricted Stock Units, such Restricted Stock Unit will represent an unsecured obligation of the Company, payable (if at all) only from the general assets of the Company.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">3.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Vesting Schedule</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Except as provided in Section 4, and subject to Section 5, the Restricted Stock Units awarded by this Award Agreement will vest in accordance with the vesting provisions set forth in the Notice of Grant.  Unless specifically provided otherwise in this Award Agreement or other written agreement between Participant and the Company or any Parent or Subsidiary of the Company, as applicable, governing the terms of this Award, Restricted Stock Units scheduled to vest on a certain date or upon the occurrence of a certain condition will not vest in accordance with any of the provisions of this Award Agreement, unless Participant will have been continuously a Service Provider from the Date of Grant until the date such vesting occurs.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">4.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Payment after Vesting.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(a)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">General Rule</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Subject to Section 7, any Restricted Stock Units that vest will be paid to Participant (or in the event of Participant&#x2019;s death, to his or her properly designated beneficiary or estate) in whole Shares.  Subject to the provisions of Section 4(c), such vested Restricted Stock Units shall be paid in whole Shares as soon as practicable after vesting, but in each such case within sixty (60) days following the vesting date.  In no event will Participant be permitted, directly or indirectly, to specify the taxable year of payment of any Restricted Stock Units payable under this Award Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(b)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Discretionary Acceleration</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Administrator, in its discretion, may accelerate the vesting of the balance, or some lesser portion of the balance, of the unvested Restricted Stock Units at any time, subject to the terms of the Plan.  If so accelerated, such Restricted Stock Units will be considered as having vested as of the date specified by the Administrator.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:7.5pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(c).	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Section 409A.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	(i)	If Participant is a U.S. taxpayer, the payment of Shares vesting pursuant to this Award Agreement (including any discretionary acceleration under Section 4(b)) shall in all cases be paid at a time or in a manner that is exempt from, or complies with, Section 409A.  The prior sentence may be superseded in a future agreement or amendment to this Award Agreement only by direct and specific reference to such sentence.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	(ii)	Notwithstanding anything in the Plan or this Award Agreement or any other agreement (whether entered into before, on or after the Date of Grant), if the vesting of the balance, or some lesser portion of the balance, of the Restricted Stock Units is accelerated in connection with the termination of Participant&#x2019;s status as a Service Provider (provided that such termination is a &#x201c;separation from service&#x201d; within the meaning of Section 409A, as determined by the Administrator), other than due to Participant&#x2019;s death, and if (x) Participant is a U.S. taxpayer and a &#x201c;specified employee&#x201d; within the meaning of Section 409A at the time of such termination as a Service Provider and (y) the payment of such accelerated Restricted Stock Units will result in the imposition of additional tax under Section 409A if paid to Participant on or within the six (6) month period following the cessation of Participant&#x2019;s status as a Service Provider, then the payment of such accelerated Restricted Stock Units will not be made until the date six (6) months and one (1) day following the date of cessation of Participant&#x2019;s status as a Service Provider, unless Participant dies following his or her termination as a Service Provider, in which case, the Restricted Stock Units will be paid in Shares to Participant&#x2019;s estate as soon as practicable following his or her death.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	(iii)	It is the intent of this Award Agreement that it and all payments and benefits to U.S. taxpayers hereunder be exempt from, or comply with, the requirements of Section 409A so that none of the Restricted Stock Units provided under this Award Agreement or Shares issuable thereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities or ambiguous terms herein will be interpreted to be so exempt or so comply.  Each payment payable under this Award Agreement is intended to constitute a separate payment for purposes of Treasury Regulations Section 1.409A-2(b)(2).  To the extent necessary to comply with Section 409A, references to termination of Participant&#x2019;s status as a Service Provider, termination of employment, or similar phrases will be references to Participant&#x2019;s &#x201c;separation from service&#x201d; within the meaning of Section 409A.  In no event will the Company or any Parent or Subsidiary of the Company have any responsibility, liability, or obligation to reimburse, indemnify, or hold harmless Participant (or any other person) for any taxes, penalties and interest that may be imposed, or other costs that may be incurred, as a result of Section 409A.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">5.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Forfeiture Upon Termination as a Service Provider</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Unless specifically provided otherwise in this Award Agreement or other written agreement between Participant and the Company or any of its Subsidiaries or Parents, as applicable, governing the terms of this Award, if Participant ceases to be a Service Provider for any or no reason, the then-unvested Restricted Stock Units awarded by this Award Agreement will thereupon be forfeited at no cost to the Company and Participant will have no further rights thereunder.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">6.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Death of Participant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Any distribution or delivery to be made to Participant under this Award Agreement, if Participant is then deceased, will be made to Participant&#x2019;s designated beneficiary, or if no beneficiary survives Participant, the administrator or executor of Participant&#x2019;s</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">estate.  Any such transferee must furnish the Company with (a) written notice of his or her status as transferee, and (b) evidence satisfactory to the Company to establish the validity of the transfer and compliance with any laws or regulations pertaining to said transfer.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">7.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tax Obligations</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	(a)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Responsibility for Taxes</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Participant acknowledges that, regardless of any action taken by the Company or, if different, Participant&#x2019;s employer or any Parent or Subsidiary of the Company to which Participant is providing services (together, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Service Recipients</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), the ultimate liability for any tax and/or social insurance liability obligations and requirements in connection with the Restricted Stock Units, including, without limitation, (i) all federal, state, and local taxes (including Participant&#x2019;s Federal Insurance Contributions Act (FICA) obligations) that are required to be withheld by any Service Recipient or other payment of tax-related items related to Participant&#x2019;s participation in the Plan and legally applicable to Participant, (ii) Participant&#x2019;s and, to the extent required by any Service Recipient, the Service Recipient&#x2019;s fringe benefit tax liability, if any, associated with the grant, vesting, or settlement of the Restricted Stock Units or sale of Shares, and (iii) any other Service Recipient taxes the responsibility for which Participant has, or has agreed to bear, with respect to the Restricted Stock Units (or settlement thereof or issuance of Shares thereunder) (collectively, the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tax Obligations</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;), is and remains Participant&#x2019;s sole responsibility and may exceed the amount actually withheld by the applicable Service Recipient(s).  Participant further acknowledges that no Service Recipient (A) makes any representations or undertakings regarding the treatment of any Tax Obligations in connection with any aspect of the Restricted Stock Units, including, but not limited to, the grant, vesting or settlement of the Restricted Stock Units, the subsequent sale of Shares acquired pursuant to such settlement and the receipt of any dividends or other distributions, and (B) makes any commitment to and is under any obligation to structure the terms of the grant or any aspect of the Restricted Stock Units to reduce or eliminate Participant&#x2019;s liability for Tax Obligations or achieve any particular tax result.  Further, if Participant is subject to Tax Obligations in more than one jurisdiction between the Date of Grant and the date of any relevant taxable or tax withholding event, as applicable, Participant acknowledges that the applicable Service Recipient(s) (or former employer, as applicable) may be required to withhold or account for Tax Obligations in more than one jurisdiction.  If Participant fails to make satisfactory arrangements for the payment of any required Tax Obligations hereunder at the time of the applicable taxable event, Participant acknowledges and agrees that the Company may refuse to issue or deliver the Shares.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	(b)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tax Withholding</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Pursuant to such procedures as the Administrator may specify from time to time, the Service Recipient will withhold the amount required to be withheld for the payment of Tax Obligations.  The Administrator, in its sole discretion and pursuant to such procedures as it may specify from time to time, may permit Participant to satisfy such Tax Obligations, in whole or in part (without limitation), if permissible by applicable local law, by:  (i) paying cash in U.S. dollars, (ii) electing to have the Company withhold otherwise deliverable Shares having a fair market value equal to the minimum amount that is necessary to meet the withholding requirement for such Tax Obligations (or such greater amount as Participant may elect if permitted by the Administrator, if such greater amount would not result in adverse financial accounting consequences), (iii) withholding the amount of such Tax Obligations from Participant&#x2019;s wages or other cash compensation paid to Participant by the applicable Service Recipient(s), (iv) delivering to the Company Shares that Participant owns and that already have vested with a fair market value equal to the Tax Obligations (or such greater amount as Participant may elect if permitted by the</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">3</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Administrator, if such greater amount would not result in adverse financial accounting consequences), (v) selling a sufficient number of such Shares otherwise deliverable to Participant, through such means as the Company may determine in its sole discretion (whether through a broker or otherwise) equal to the minimum amount that is necessary to meet the withholding requirement for such Tax Obligations (or such greater amount as Participant may elect if permitted by the Administrator, if such greater amount would not result in adverse financial accounting consequences), or (vi) such other means as the Administrator deems appropriate.  If the Tax Obligations are satisfied by withholding in Shares, for tax purposes, Participant is deemed to have been issued the full number of Shares subject to the vested Restricted Stock Units, notwithstanding that a number of the Shares are held back solely for the purpose of paying the Tax Obligations. To the extent determined appropriate by the Administrator in its discretion, the Administrator will have the right (but not the obligation) to satisfy any Tax Obligations by reducing the number of Shares otherwise deliverable to Participant.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	(c)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Tax Consequences</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Participant has reviewed with his or her own tax advisers the U.S. federal, state, local and non-U.S. tax consequences of this investment and the transactions contemplated by this Award Agreement.  With respect to such matters, Participant relies solely on such advisers and not on any statements or representations of the Company or any of its agents, written or oral.  Participant understands that Participant (and not the Company) shall be responsible for Participant&#x2019;s own tax liability that may arise as a result of this investment or the transactions contemplated by this Award Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	(d)	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Company&#x2019;s Obligation to Deliver Shares</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  For clarification purposes, in no event will the Company issue Participant any Shares unless and until arrangements satisfactory to the Administrator have been made for the payment of Participant&#x2019;s Tax Obligations.  If Participant fails to make satisfactory arrangements for the payment of such Tax Obligations hereunder at the time any applicable Restricted Stock Units otherwise are scheduled to vest pursuant to Sections 3 or 4 or Participant&#x2019;s Tax Obligations otherwise become due, Participant permanently will forfeit such Restricted Stock Units to which Participant&#x2019;s Tax Obligation relates and any right to receive Shares thereunder and such Restricted Stock Units will be returned to the Company at no cost to the Company.  Participant acknowledges and agrees that the Company may refuse to issue or deliver the Shares if such Tax Obligations are not delivered at the time they are due.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">8. </font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Rights as Stockholder</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Neither Participant nor any person claiming under or through Participant will have any of the rights or privileges of a stockholder of the Company in respect of any Shares deliverable hereunder unless and until certificates representing such Shares (which may be in book entry form) will have been issued, recorded on the records of the Company or its transfer agents or registrars, and delivered to Participant (including through electronic delivery to a brokerage account).  After such issuance, recordation and delivery, Participant will have all the rights of a stockholder of the Company with respect to voting such Shares and receipt of dividends and distributions on such Shares.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">9.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Guarantee of Continued Service</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  PARTICIPANT ACKNOWLEDGES AND AGREES THAT THE VESTING OF THE RESTRICTED STOCK UNITS PURSUANT TO THE VESTING SCHEDULE HEREOF IS EARNED ONLY BY CONTINUING AS A SERVICE PROVIDER, WHICH UNLESS PROVIDED OTHERWISE UNDER APPLICABLE LAWS IS AT THE WILL OF THE APPLICABLE SERVICE RECIPIENT AND NOT THROUGH THE ACT OF</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">4</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">BEING HIRED, BEING GRANTED THIS RESTRICTED STOCK UNIT AWARD OR ACQUIRING SHARES HEREUNDER.  PARTICIPANT FURTHER ACKNOWLEDGES AND AGREES THAT THIS AWARD AGREEMENT, THE TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS A SERVICE PROVIDER FOR THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND SHALL NOT INTERFERE IN ANY WAY WITH PARTICIPANT&#x2019;S RIGHT OR THE RIGHT OF ANY SERVICE RECIPIENT TO TERMINATE PARTICIPANT&#x2019;S RELATIONSHIP AS A SERVICE PROVIDER, SUBJECT TO APPLICABLE LAW, WHICH TERMINATION, UNLESS PROVIDED OTHERWISE UNDER APPLICABLE LAW, MAY BE AT ANY TIME, WITH OR WITHOUT CAUSE.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">10.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Grant is Not Transferable</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Except to the limited extent provided in Section 6, this Award and the rights and privileges conferred hereby will not be transferred, assigned, pledged or hypothecated in any way (whether by operation of law or otherwise) and will not be subject to sale under execution, attachment or similar process.  Upon any attempt to transfer, assign, pledge, hypothecate or otherwise dispose of this Award, or any right or privilege conferred hereby, or upon any attempted sale under any execution, attachment or similar process, this Award and the rights and privileges conferred hereby immediately will become null and void.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">11.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Nature of Grant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  In accepting this Award of Restricted Stock Units, Participant acknowledges, understands and agrees that:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	(a)	the grant of the Restricted Stock Units is voluntary and occasional and does not create any contractual or other right to receive future grants of Restricted Stock Units, or benefits in lieu of Restricted Stock Units, even if Restricted Stock Units have been granted in the past;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	(b)	all decisions with respect to future Restricted Stock Units or other grants, if any, will be at the sole discretion of the Administrator;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	(c)	Participant is voluntarily participating in the Plan;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	(d)	the Restricted Stock Units and the Shares subject to the Restricted Stock Units are not intended to replace any pension rights or compensation;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	(e)	the Restricted Stock Units and the Shares subject to the Restricted Stock Units, and the income and value of same, are not part of normal or expected compensation for purposes of calculating any severance, resignation, termination, redundancy, dismissal, end-of-service payments, bonuses, long-service awards, pension or retirement or welfare benefits or similar payments;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	(f)	the future value of the Shares underlying the Restricted Stock Units is unknown, indeterminable and cannot be predicted;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	(g)	for purposes of the Restricted Stock Units, Participant&#x2019;s status as a Service Provider will be considered terminated as of the date Participant is no longer actively providing services to the Company or any Parent or Subsidiary (regardless of the reason for such termination and whether or not later found to be invalid or in breach of employment laws in the jurisdiction</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">5</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">where Participant is a Service Provider or the terms of Participant&#x2019;s employment or service agreement, if any), and unless otherwise expressly provided in this Award Agreement (including by reference in the Notice of Grant to other arrangements or contracts) or determined by the Administrator, Participant&#x2019;s right to vest in the Restricted Stock Units under the Plan, if any, will terminate as of such date and will not be extended by any notice period (e.g., Participant&#x2019;s period of service would not include any contractual notice period or any period of &#x201c;garden leave&#x201d; or similar period mandated under employment laws in the jurisdiction where Participant is a Service Provider or the terms of Participant&#x2019;s employment or service agreement, if any, unless Participant is providing bona fide services during such time); the Administrator shall have the exclusive discretion to determine when Participant is no longer actively providing services for purposes of this Award of Restricted Stock Units (including whether Participant may still be considered to be providing services while on a leave of absence and consistent with local law);</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	(h)	unless otherwise provided in the Plan or by the Administrator in its discretion, the Restricted Stock Units and the benefits evidenced by this Award Agreement do not create any entitlement to have the Restricted Stock Units or any such benefits transferred to, or assumed by, another company nor be exchanged, cashed out or substituted for, in connection with any corporate transaction affecting the Shares; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">	(i)	 the following provisions apply only if Participant is providing services outside the United States:</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">		(i)	the Restricted Stock Units and the Shares subject to the Restricted Stock Units are not part of normal or expected compensation or salary for any purpose;</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">		(ii)	Participant acknowledges and agrees that no Service Recipient shall be liable for any foreign exchange rate fluctuation between Participant&#x2019;s local currency and the United States Dollar that may affect the value of the Restricted Stock Units or of any amounts due to Participant pursuant to the settlement of the Restricted Stock Units or the subsequent sale of any Shares acquired upon settlement; and</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">		(iii)	no claim or entitlement to compensation or damages shall arise from forfeiture of the Restricted Stock Units resulting from the termination of Participant&#x2019;s status as a Service Provider (for any reason whatsoever whether or not later found to be invalid or in breach of employment laws in the jurisdiction where Participant is a Service Provider or the terms of Participant&#x2019;s employment or service agreement, if any), and in consideration of the grant of the Restricted Stock Units to which Participant is otherwise not entitled, Participant irrevocably agrees never to institute any claim against any Service Recipient, waives his or her ability, if any, to bring any such claim, and releases each Service Recipient from any such claim; if, notwithstanding the foregoing, any such claim is allowed by a court of competent jurisdiction, then, by participating in the Plan, Participant shall be deemed irrevocably to have agreed not to pursue such claim and agrees to execute any and all documents necessary to request dismissal or withdrawal of such claim.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">12.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Advice Regarding Grant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding Participant&#x2019;s participation in the Plan, or Participant&#x2019;s acquisition or sale of the Shares underlying the Restricted Stock Units.  Participant is hereby advised to consult with his or her own personal tax, legal and</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">6</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">financial advisers regarding his or her participation in the Plan before taking any action related to the Plan.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">13.	</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Data Privacy</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">.  Participant hereby explicitly and unambiguously consents to the collection, use and transfer, in electronic or other form, of Participant&#x2019;s personal data as described in this Award Agreement and any other Restricted Stock Unit grant materials by and among, as applicable, the Service Recipients for the exclusive purpose of implementing, administering and managing Participant&#x2019;s participation in the Plan.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Participant understands that the Company and the Service Recipient may hold certain personal information about Participant, including, but not limited to, Participant&#x2019;s name, home address and telephone number, date of birth, social insurance number or other identification number, salary, nationality, job title, any Shares or directorships held in the Company, details of all Restricted Stock Units or any other entitlement to Shares awarded, canceled, exercised, vested, unvested or outstanding in Participant&#x2019;s favor (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Data</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#x201d;), for the exclusive purpose of implementing, administering and managing the Plan.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Participant understands that Data may be transferred to a stock plan service provider, as may be selected by the Company in the future, assisting the Company with the implementation, administration and management of the Plan.  Participant understands that the recipients of the Data may be located in the United States or elsewhere, and that the recipients&#x2019; country of operation (e.g., the United States) may have different data privacy laws and protections than Participant&#x2019;s country.  Participant understands that if he or she resides outside the United States, he or she may request a list with the names and addresses of any potential recipients of the Data by contacting his or her local human resources representative.  Participant authorizes the Company, any stock plan service provider selected by the Company and any other possible recipients which may assist the Company (presently or in the future) with implementing, administering and managing the Plan to receive, possess, use, retain and transfer the Data, in electronic or other form, for the sole purpose of implementing, administering and managing his or her participation in the Plan.  Participant understands that Data will be held only as long as is necessary to implement, administer and manage Participant&#x2019;s participation in the Plan.  Participant understands if he or she resides outside the United States, he or she may, at any time, view Data, request additional information about the storage and processing of Data, require any necessary amendments to Data or refuse or withdraw the consents herein, in any case without cost, by contacting in writing his or her local human resources representative.  Further, Participant understands that he or she is providing the consents herein on a purely voluntary basis.  If Participant does not consent, or if Participant later seeks to revoke his or her consent, his or her status as a Service Provider and career with the Service Recipient will not be adversely affected.  The only adverse consequence of refusing or withdrawing Participant&#x2019;s consent is that the Company would not be able to grant Participant Restricted Stock Units or other equity awards or administer or maintain such awards.  Therefore, Participant understands that refusing or withdrawing his or her consent may affect Participant&#x2019;s ability to participate in the Plan.  For more information on the consequences of Participant&#x2019;s refusal to consent or withdrawal of consent, Participant understands that he or she may contact his or her local human resources representative.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">7</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">14.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Address for Notices</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Any notice to be given to the Company under the terms of this Award Agreement will be addressed to the Company at Athira Pharma, Inc., 400 Mason Rd., Suite 300, Seattle, Washington 98195-2141, or at such other address as the Company may hereafter designate in writing.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">15.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Successors and Assigns</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company may assign any of its rights under this Award Agreement to single or multiple assignees, and this Award Agreement shall inure to the benefit of the successors and assigns of the Company.  Subject to the restrictions on transfer herein set forth, this Award Agreement shall be binding upon Participant and his or her heirs, executors, administrators, successors and assigns.  The rights and obligations of Participant under this Award Agreement may be assigned only with the prior written consent of the Company.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">16.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Additional Conditions to Issuance of Stock</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  If at any time the Company will determine, in its discretion, that the listing, registration, qualification or rule compliance of the Shares upon any securities exchange or under any state, federal or non-U.S. law, the tax code and related regulations or under the rulings or regulations of the U.S. Securities and Exchange Commission or any other governmental regulatory body or the clearance, consent or approval of the U.S. Securities and Exchange Commission or any other governmental regulatory authority is necessary or desirable as a condition to the issuance of Shares to Participant (or his or her estate) hereunder, such issuance will not occur unless and until such listing, registration, qualification, rule compliance, clearance, consent or approval will have been completed, effected or obtained free of any conditions not acceptable to the Company.  Subject to the terms of the Award Agreement and the Plan, the Company will not be required to issue any certificate or certificates for (or make any entry on the books of the Company or of a duly authorized transfer agent of the Company of) the Shares hereunder prior to the lapse of such reasonable period of time following the date of vesting of the Restricted Stock Units as the Administrator may establish from time to time for reasons of administrative convenience.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">17.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Language</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  If Participant has received this Award Agreement or any other document related to the Plan translated into a language other than English and if the meaning of the translated version is different than the English version, the English version will control.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">18.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Interpretation</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Administrator will have the power to interpret the Plan and this Award Agreement and to adopt such rules for the administration, interpretation and application of the Plan as are consistent therewith and to interpret or revoke any such rules (including, but not limited to, the determination of whether or not any Restricted Stock Units have vested).  All actions taken and all interpretations and determinations made by the Administrator in good faith will be final and binding upon Participant, the Company and all other interested persons.  Neither the Administrator nor any person acting on behalf of the Administrator will be personally liable for any action, determination or interpretation made in good faith with respect to the Plan or this Award Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">19.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Electronic Delivery and Acceptance</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Company may, in its sole discretion, decide to deliver any documents related to the Restricted Stock Units awarded under the Plan or future Restricted Stock Units that may be awarded under the Plan by electronic means or require Participant to participate in the Plan by electronic means.  Participant hereby consents to receive such documents by electronic delivery and agrees to participate in the Plan through any on-line or</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">8</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">electronic system established and maintained by the Company or a third party designated by the Company.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">20.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Captions</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Captions provided herein are for convenience only and are not to serve as a basis for interpretation or construction of this Award Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">21.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Amendment, Suspension or Termination of the Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  By accepting this Award, Participant expressly warrants that he or she has received an Award of Restricted Stock Units under the Plan, and has received, read and understood a description of the Plan.  Participant understands that the Plan is discretionary in nature and may be amended, suspended or terminated by the Administrator at any time.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">22.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Country Addendum</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Notwithstanding any provisions in this Award Agreement, the Restricted Stock Unit grant shall be subject to any special terms and conditions set forth in an appendix (if any) to this Award Agreement for any country whose laws are applicable to Participant and this Award of Restricted Stock Units (as determined by the Administrator in its sole discretion) (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Country Addendum</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;).  Moreover, if Participant relocates to one of the countries included in the Country Addendum (if any), the special terms and conditions for such country will apply to Participant, to the extent the Company determines that the application of such terms and conditions is necessary or advisable for legal or administrative reasons.  The Country Addendum constitutes part of this Award Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">23.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Modifications to the Award Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  This Award Agreement constitutes the entire understanding of the parties on the subjects covered.  Participant expressly warrants that he or she is not accepting this Award Agreement in reliance on any promises, representations, or inducements other than those contained herein.  Modifications to this Award Agreement can be made only in an express written contract executed by a duly authorized officer of the Company.  Notwithstanding anything to the contrary in the Plan or this Award Agreement, the Company reserves the right to revise this Award Agreement as it deems necessary or advisable, in its sole discretion and without the consent of Participant, to comply with Section 409A or to otherwise avoid imposition of any additional tax or income recognition under Section 409A in connection with this Award of Restricted Stock Units.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">24.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">No Waiver</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  Either party&#x2019;s failure to enforce any provision or provisions of this Award Agreement shall not in any way be construed as a waiver of any such provision or provisions, nor prevent that party from thereafter enforcing each and every other provision of this Award Agreement.  The rights granted both parties herein are cumulative and shall not constitute a waiver of either party&#x2019;s right to assert all other legal remedies available to it under the circumstances.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">25.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Governing Law; Severability</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  This Award Agreement and the Restricted Stock Units are governed by the internal substantive laws, but not the choice of law rules, of the State of Delaware.  In the event that any provision hereof becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable or void, this Award Agreement shall continue in full force and effect.</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">26.	</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Entire Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.  The Plan is incorporated herein by reference.  The Plan and this Award Agreement (including the exhibits, appendices, and addenda attached to the Notice of Grant)</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">9</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety all prior undertakings and agreements of the Company and Participant with respect to the subject matter hereof, and may not be modified adversely to the Participant&#x2019;s interest except by means of a writing signed by the Company and Participant.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">*          *          *</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">10</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">-</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.6in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">APPENDIX A</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ATHIRA PHARMA, INC.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2024 INDUCEMENT EQUITY INCENTIVE PLAN</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">COUNTRY ADDENDUM TO RESTRICTED STOCK UNIT AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Unless otherwise defined herein, capitalized terms used in this Country Addendum to Restricted Stock Unit Agreement (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Country Addendum</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) will be ascribed the same defined meanings as set forth in the Restricted Stock Unit Agreement of which this Country Addendum forms a part (or the Plan or other written agreement as specified in the Restricted Stock Unit Agreement).</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Terms and Conditions</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Country Addendum includes additional terms and conditions that govern the Award of Restricted Stock Units granted pursuant to the terms and conditions of the Athira Pharma, Inc. 2024 Inducement Equity Incentive Plan (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Plan</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) and the Restricted Stock Unit Agreement to which this Country Addendum is attached (the &#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Restricted Stock Unit Agreement</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) to the extent the individual to whom the Restricted Stock Units were granted (&#x201c;</font><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Participant</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201d;) resides and/or works in one of the countries listed below.  If the Participant is a citizen or resident (or is considered as such for local law purposes) of a country other than the country in which the Participant is currently residing and/or working, or if the Participant relocates to another country after the Award of Restricted Stock Units is granted, the Company, in its discretion, will determine to what extent the terms and conditions contained herein will apply to the Participant.</font></p>
  <p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Notifications</font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">This Country Addendum also may include information regarding exchange controls and certain other issues of which Participant should be aware with respect to his or her participation in the Plan.  The information is based on the securities, exchange control and other Applicable Laws in effect in the respective countries as of [______].  Such Applicable Laws often are complex and change frequently.  As a result, the Company strongly recommends that Participant not rely on the information in this Country Addendum as the only source of information relating to the consequences of Participant&#x2019;s participation in the Plan because the information may be out of date at the time Participant vests in or receives or sells the Shares covered by the Restricted Stock Units.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In addition, the information contained in this Country Addendum is general in nature and may not apply to Participant&#x2019;s particular situation, and the Company is not in a position to assure Participant of any particular result.  Participant should seek appropriate professional advice as to how the Applicable Laws in Participant&#x2019;s country may apply to his or her situation.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <p style="text-indent:6.667%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Finally, if Participant is a citizen or resident of a country other than the one in which Participant currently is residing and/or working, transfers residence and/or employment to another country after the grant of the Restricted Stock Units, or is considered a resident of another country for local law purposes, the information in this Country Addendum may not apply to Participant in the same manner.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.6in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>atha-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Exhibit 99.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><img src="img247042425_0.jpg" alt="img247042425_0.jpg" style="width:174px;height:86px;">&#160;</p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:14pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:14pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:14pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Enrollment completed in Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer&#x2019;s disease; topline data expected in second half of 2024</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">On track to initiate first-in-human studies of ATH-1105 for the treatment of amyotrophic lateral sclerosis in first half of 2024</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Strong balance sheet to support innovative pipeline through key inflection points</font></p>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">BOTHELL, Wash., February 22, 2024 &#x2013; Athira Pharma, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today reported financial results for the year ended December 31, 2023, and reviewed recent pipeline and business updates.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x201c;We&#x2019;ve made important progress in our pursuit to advance potential new treatment options for neurodegenerative diseases. Importantly, in January, we announced completing enrollment in our Phase 2/3 LIFT-AD clinical trial, which is evaluating fosgonimeton in approximately 315 patients with mild-to-moderate Alzheimer&#x2019;s disease,&#x201d; stated Mark Litton, Ph.D., President and Chief Executive Officer of Athira. &#x201c;We are encouraged by results shown to date, which we believe support fosgonimeton&#x2019;s potential to deliver a first-in-class therapy to Alzheimer&#x2019;s disease patients and expect to report topline data from LIFT-AD in the second half of 2024. Additionally, we are excited to advance ATH-1105 for the potential treatment of ALS and remain on-track to initiate the first-in-human study in the first half of 2024. We ended 2023 with a strong balance sheet that we believe will support the ongoing advancement of our pipeline, including fosgonimeton and ATH-1105, through key inflection points.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Recent Highlights</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Pipeline</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In February 2024, the Company announced publication of research highlighting the neuroprotective and anti-inflammatory effects of ATH-1105 in preclinical models of amyotrophic lateral sclerosis (ALS) in the peer-reviewed journal, </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Frontiers in Neuroscience. </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The original research article is titled: &#x201c;ATH-1105, a small-molecule positive modulator of the neurotrophic HGF system, is neuroprotective, preserves neuromotor function, and extends survival in preclinical models of ALS.&#x201d;  </font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In January 2024, the Company completed enrollment in the Phase 2/3 LIFT-AD clinical trial of fosgonimeton as a potential treatment for mild-to-moderate Alzheimer&#x2019;s disease (AD). The Phase 2/3 LIFT-AD clinical trial enrolled approximately 315 patients. </font></div></div>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:14pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In December 2023, the Company announced encouraging results from the exploratory Phase 2 SHAPE clinical trial to evaluate fosgonimeton in patients with Parkinson's disease dementia and dementia with Lewy bodies.</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In December 2023, the Company presented preclinical data at the Motor Neurone Disease Association (MNDA) 34</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> International Symposium on ALS/MND demonstrating ATH-1105 is neuroprotective, extends survival, reduces motor and nerve function decline when administered early or late in disease progression</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">and is effective in combination with riluzole in a transgenic mouse model of ALS.</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In November 2023, the Company presented new preclinical data at the Society for Neuroscience (SfN) Annual Meeting</font><font style="color:#000000;white-space:pre-wrap;font-size:15pt;font-family:'Georgia',serif;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">2023 highlighting the anti-inflammatory activity of fosgonimeton in microglial models, as well as the neuroprotective and procognitive effects of fosgonimeton in amyloid-&#x3b2; models of Alzheimer&#x2019;s disease.</font></div></div>
  <p style="font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Corporate</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In February 2024, Rachel Lenington, the Company&#x2019;s Chief Operating Officer, was appointed as Chief Operating Officer and Chief Development Officer, and Samantha Willing was appointed as Chief People Officer.   </font></div></div>
  <p style="font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Upcoming Presentations</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Athira will present clinical and preclinical data at the 18</font><font style="color:#000000;white-space:pre-wrap;vertical-align:super;font-size:7.37pt;font-family:'Calibri',sans-serif;min-width:fit-content;">th</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> International Conference on Alzheimer&#x2019;s and Parkinson&#x2019;s Diseases (AD/PD 2024) taking place March 5-9, 2024, in Lisbon, Portugal. Presentation details include:</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Abstract Title:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Results from SHAPE: A Phase 2 Study of Fosgonimeton in Patients with Parkinson&#x2019;s Disease Dementia and Dementia with Lewy Bodies </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#x2013; Poster #: P1050/#1857: Presenter: Hans Moebius, M.D., Ph.D., Senior Scientific Advisor</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Abstract Title:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Neuroprotective mechanisms of Fosgonimeton Against Excitotoxicity in Primary Neuron Culture</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> &#x2013; Poster #: P0256/#1757; Presenter: Sherif Reda, Ph.D., Associate Director, Discovery Biology</font></div></div>
  <div style="margin-left:10%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:Times New Roman;min-width:3.7033333333333336%;display:inline-flex;justify-content:flex-start;">o</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Abstract Title:</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Fosgonimeton protects against &#x3b1;-synuclein-mediated pathology in preclinical models of Parkinson&#x2019;s disease</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> &#x2013; Poster #: P1046/#1243; Presenter: Sharay Setti, Ph.D., Senior Scientist II</font></div></div>
  <p style="font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Clinical Development &amp; Pipeline Programs</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Athira&#x2019;s drug development pipeline includes potential first-in-class (fosgonimeton) and next-generation (ATH-1105 and ATH-1020) small molecule drug candidates designed to promote the neurotrophic hepatocyte growth factor (HGF) system, which activates neuroprotective, neurotrophic and anti-inflammatory pathways in the central nervous system. Athira&#x2019;s drug candidates have distinct properties, which the Company believes may be applicable to a broad range of neurodegenerative diseases.</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:14pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Fosgonimeton (ATH-1017)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> &#x2013; A potentially first-in-class, once daily, subcutaneously administered drug candidate initially targeted for the potential treatment of Alzheimer&#x2019;s disease.</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">LIFT-AD Phase 2/3 clinical trial of fosgonimeton in mild-to-moderate Alzheimer&#x2019;s disease </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">(</font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">NCT04488419</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The LIFT-AD study is investigating the effects of fosgonimeton 40 mg compared with placebo in mild-to-moderate AD patients who are not receiving background therapy. </font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In October 2022, following an unblinded interim efficacy and futility analysis, an independent data monitoring committee recommended continuation of the LIFT-AD study in patients with mild-to-moderate AD who are not receiving background therapy.  The committee also determined that the study would be well powered to achieve the primary endpoint with approximately 300 patients given the preliminary effect observed in the unblinded interim analysis of approximately 100 patients treated. </font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In May 2023, Athira selected the 40 mg dose for further development and potential regulatory approval.</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In January 2024, Athira completed enrollment of the LIFT-AD study, randomizing approximately 315 patients in the primary analysis population.</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The Company expects to report topline data in the second half of 2024.  </font></div></div>
  <p style="text-indent:3.333%;font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">Open Label Extension (OLEX) fosgonimeton trial </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">(</font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">NCT04886063</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">)</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Eligible participants who complete the LIFT-AD or ACT-AD trials and elect to participate in the ongoing OLEX are able to receive up to 30 months of open-label treatment.</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Greater than 85% of participants who completed either study have elected to enroll in OLEX to date.</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Currently, more than 60 patients are continuing fosgonimeton treatment beyond 18 months, which is unexpected in a progressive mild-to-moderate Alzheimer&#x2019;s disease population.</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Athira believes the OLEX will complement its long-term safety database and provide insights into fosgonimeton&#x2019;s long-term effects for up to three years of investigational treatment.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="margin-left:3.333%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">SHAPE Phase 2 clinical trial of fosgonimeton in mild-to-moderate Parkinson&#x2019;s disease dementia and Dementia with Lewy bodies </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">(</font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">NCT04831281</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">)</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">In December 2023, Athira announced encouraging results from the exploratory SHAPE Phase 2 clinical trial of fosgonimeton for the potential treatment of Parkinson's disease dementia and dementia with Lewy bodies.  </font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Treatment with fosgonimeton 40 mg (n=5) compared to placebo (n=7) showed positive effects in cognitive measures including ADAS-Cog13, MMSE, and COWAT over the 6-month double-blind treatment period.</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The primary endpoint of the trial, a composite score of the change in Event-Related-Potential (ERP) P300 latency and cognitive assessment (ADAS-Cog13), was not met by protocoled analysis compared with placebo.</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Fosgonimeton was generally well tolerated, with a favorable safety profile. There were no treatment-related serious adverse events observed in the study.  The most common adverse event in the treatment groups was injection site reactions.   </font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:14pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ATH-1105</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> &#x2013; A next-generation, orally administered, small molecule drug candidate in development for the potential treatment of ALS as the Company&#x2019;s initial indication.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ATH-1105&#x2019;s potential is supported by a growing body of preclinical evidence demonstrating statistically significant improvements on nerve and motor function, biomarkers of inflammation and neurodegeneration, and survival in various animal models of ALS. </font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">These data were presented throughout 2023 at a variety of key scientific and medical meetings including the American Association of Neurology (AAN), the Alzheimer&#x2019;s Association International Congress (AAIC), the Northeast Amyotrophic Lateral Sclerosis Consortium&#174; (NEALS), and the Motor Neurone Disease Association (MNDA).</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">The Company expects to initiate the first-in-human studies of ATH-1105 in the first half of 2024.</font></div></div>
  <p style="font-size:10pt;margin-top:13.5pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Financial Results</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Cash Position</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">. Cash, cash equivalents and investments were $147.4 million as of December 31, 2023, compared to $245.2 million as of December 31, 2022. Cash used in operations was $100.8 million for the year ended December 31, 2023, compared to $72.5 million for the year ended December 31, 2022.<br></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Research and Development (R&amp;D) Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">. R&amp;D expenses were $93.8 million for the year ended December 31, 2023, compared to $61.5 million for the year ended December 31, 2022. The increase was driven primarily by costs related to increased clinical trial and manufacturing activities, personnel costs, and preclinical research and development expenses.  <br></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">General and Administrative (G&amp;A) Expenses</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">G&amp;A expenses were $33.3 million for the year ended December 31, 2023, compared to $32.6 million for the year ended December 31, 2022</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;font-style:italic;min-width:fit-content;">.</font></div></div>
  <p style="margin-left:6.667%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Legal Settlement Expense and Insurance Recovery</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">. In February 2023, the Company reached an agreement in principle to resolve all claims in the Company&#x2019;s securities class action lawsuit. Under the proposed settlement, the Company agreed to make a one-time payment of $10.0 million and recorded a legal settlement expense of $10.0 million for the year ended December 31, 2022. Additionally, the Company recorded an insurance recovery of $1.6 million for the year ended December 31, 2023, representing the amount to be covered by the Company&#x2019;s insurers.<br></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:3.447919145106397%;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Net Loss</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">. Net loss was $117.7 million, or $3.09 per share, for the year ended December 31, 2023, compared to a net loss of $95.6 million, or $2.53 per share, for the year ended December 31, 2022.</font></div></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">About Athira Pharma, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"><br>Athira Pharma, Inc., headquartered in the Seattle, Washington area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. Athira aims to alter the course of neurological diseases by advancing its pipeline of drug candidates that modulate the neurotrophic HGF system. For more information, visit </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">w</font></font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">ww.athira.com</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">. You can also follow Athira on </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Facebook</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">, </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">LinkedIn</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">, </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">X</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> (formerly known as Twitter) and </font><font><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Instagram</font></font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:14pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Forward-Looking Statements</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"><br>This communication contains &#x201c;forward-looking statements&#x201d; within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include statements regarding: drug candidates as a potential treatment for Alzheimer&#x2019;s disease, Parkinson&#x2019;s disease, Parkinson&#x2019;s disease dementia, Dementia with Lewy bodies, amyotrophic lateral sclerosis, and other neurodegenerative diseases; future development plans; the anticipated reporting of data; the potential learnings from preclinical studies, the ACT-AD and SHAPE trials, and LIFT-AD unblinded interim efficacy and futility analysis and their ability to inform and improve future clinical development plans; expectations regarding the potential efficacy and commercial potential of Athira&#x2019;s drug candidates;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">and Athira&#x2019;s ability to advance its drug candidates into later stages of development. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as &#x201c;may,&#x201d; &#x201c;will,&#x201d; &#x201c;should,&#x201d; &#x201c;on track,&#x201d; &#x201c;would,&#x201d; &#x201c;expect,&#x201d; &#x201c;plan,&#x201d; &#x201c;believe,&#x201d; &#x201c;intend,&#x201d; &#x201c;pursue,&#x201d; &#x201c;continue,&#x201d; &#x201c;suggest,&#x201d; &#x201c;potential,&#x201d; and similar expressions. Any forward-looking statements are based on management&#x2019;s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the data from preclinical and clinical trials may not support the safety, efficacy and tolerability of Athira&#x2019;s drug candidates; development of drug candidates may cease or be delayed; regulatory authorities could object to protocols, amendments and other submissions; future potential regulatory milestones for drug candidates, including those related to current and planned clinical studies, may be insufficient to support regulatory submissions or approval; Athira may not be able to recruit sufficient patients for its clinical trials; the outcome of legal proceedings that have been or may in the future be instituted against Athira, its directors and officers; possible negative interactions of Athira's drug candidates with other treatments; Athira&#x2019;s assumptions regarding its financial condition and the sufficiency of its cash, cash equivalents and investments to fund its planned operations may be incorrect; adverse conditions in the general domestic and global economic markets; the impact of competition; regulatory agencies may be delayed in reviewing, commenting on or approving any of Athira&#x2019;s clinical development plans as a result of pandemics or health epidemics, which could further delay development timelines; the impact of expanded drug candidate development and clinical activities on operating expenses; the impact of new or changing laws and regulations; as well as the other risks detailed in Athira&#x2019;s filings with the Securities and Exchange Commission from time to time. These forward-looking statements speak only as of the date hereof and Athira undertakes no obligation to update forward-looking statements. Athira may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on the forward-looking statements.</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"> </font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Investor &amp; Media Contact:</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Julie Rathbun<br>Athira Pharma<br></font><font style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">Julie.rathbun@athira.com</font><font style="color:#000000;white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;"><br>206-769-9219</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:14pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Athira Pharma, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Condensed Consolidated Balance Sheets</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">(Amounts in thousands)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.84%;"></td>
    <td style="width:1.46%;"></td>
    <td style="width:1.52%;"></td>
    <td style="width:12.6%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.48%;"></td>
    <td style="width:1.52%;"></td>
    <td style="width:12.58%;"></td>
    <td style="width:1%;"></td>
   </tr>
   <tr style="height:11pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;"> </font></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;">December 31,</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:'Helvetica LT Pro',sans-serif;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Assets</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;Cash and cash equivalents</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">90,584</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">95,966</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;Short-term investments</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">56,835</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">104,378</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;Other short-term assets</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">7,310</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">7,189</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;Long-term investments</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#x2014;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">44,829</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;Other long-term assets</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">5,516</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">5,791</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total assets</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">160,245</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">258,153</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Liabilities and stockholders' equity</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;Current liabilities</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">28,840</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">21,431</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;Long-term liabilities</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">1,217</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">1,585</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total liabilities</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">30,057</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">23,016</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Stockholders' equity</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">130,188</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">235,137</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#cff0fc;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total liabilities and stockholders' equity</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">160,245</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">258,153</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
  <div style="padding-top:0.5in;min-height:1in;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:14pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Athira Pharma, Inc.</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Arial;min-width:fit-content;">Condensed Consolidated Statements of Operations and Comprehensive Loss</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;" id="range_a1_e16"><font style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Arial;min-width:fit-content;">(Amounts in thousands, except share and per share amounts)</font></p>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:11pt;font-family:Arial;min-width:fit-content;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67%;"></td>
    <td style="width:1.62%;"></td>
    <td style="width:1%;"></td>
    <td style="width:12.88%;"></td>
    <td style="width:1%;"></td>
    <td style="width:1.62%;"></td>
    <td style="width:1%;"></td>
    <td style="width:12.88%;"></td>
    <td style="width:1%;"></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td colspan="6" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">Year Ended December 31,</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:8pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2023</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td colspan="2" style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;">2022</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#d1f4ff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Operating expenses:</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:13.7pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:13.7pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Research and development</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">93,790</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">61,464</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#d1f4ff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:13.7pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:13.7pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">General and administrative</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">33,304</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">32,552</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#ffffff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:13.7pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:13.7pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Legal settlement</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#x2014;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">10,000</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#d1f4ff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:13.7pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:13.7pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Insurance recovery related to legal settlement</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(1,628)</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#x2014;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;text-indent:27.35pt;vertical-align:top;padding-right:0.01in;"><p style="margin-left:27.35pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Total operating expenses</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">125,466</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">104,016</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#d1f4ff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Loss from operations</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(125,466</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(104,016</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Grant income</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">157</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">5,161</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#d1f4ff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Other income, net</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">7,637</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">3,216</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net loss</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(117,672</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(95,639</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#d1f4ff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Unrealized gain (loss) on available-for-sale securities</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">1,607</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(1,568</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:0.25pt solid #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:middle;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Comprehensive loss attributable to common stockholders</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(116,065</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(97,207</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:10pt;background-color:#d1f4ff;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Net loss per share attributable to common stockholders,</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;basic and diluted</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(3.09</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">)</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">$</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">(2.53</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">)</font></p></td>
   </tr>
   <tr style="height:10pt;white-space:pre-wrap;word-break:break-word;">
    <td style="padding-top:0.01in;vertical-align:top;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">Weighted-average shares used in computing net loss per</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;share attributable to common stockholders, basic</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">&#160;&#160;&#160;and diluted</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">38,020,182</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #000000;padding-right:0.01in;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;">37,733,240</font></p></td>
    <td style="padding-top:0.01in;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;padding-right:0.01in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-family:Arial;min-width:fit-content;"> </font></p></td>
   </tr>
  </table>
  <p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
  <div style="flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:11pt;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</font></p></div>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>img247042425_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img247042425_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %8 K4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5CY5R#&Z^O''ZU[?7+4AR2L;0E=!1116904444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !114<\T=O"\TK!409)-)NVK&E?1$
ME%<PWC6S$A MYBO8\<U(GC/3F^]'.OU4'^M<RQN'?VD=+P6(7V6='16(GBO2
M7ZSNI_VHS5J/7M+EQMOH<GL6Q6D<12EM)?>9RP]:.\7]QHT5"EW;RC*3QM]&
M%2@@]"*U33V,FFMQ:***8@HHHH **** "JU_>Q6%I)<3'"J.!ZGTJ=W6-"[L
M%51DD]A7GFOZR=5NML9(MHSA!_>]ZY,7B50A?J]CKP>&=>=NBW,^^O)=0O)+
MF8_,QX'H/2K6AZ4VJ7ZH01"GS2-[>E4;>"2ZN$@B4L[G %>E:3IL>EV*P)@M
MU=O[QKQL'AWB*G-/9;GLXW$+#T^2&[V\BZB+'&J( %48 %>=^)CG7I_; _2O
M1J\V\1G.OW7L0/TKT,UTHI>9Y^5:UF_(L^$@#KR'TC;^5>@5P7@[_D-M_P!<
MC_,5WM7E:_<?,C-/X_R04445Z)YP4444 %%%% !7(_$75?[.\,2PHV);L^4,
M=<=_TKKJ\;^)6J&_\1+91'<MLNT =W/^16E*-Y$3=D<5177^,/# T32=)G1<
M%HMDYQ_'UKD*[8R4E=&#5M"6UN7L[N&YC.'B<.,>U?16G7B:AIUO=QD%)HPX
MQ[BOG"O7?A=JWVK19M.D;+VKY3_<;_Z^:QQ$;JY=-ZV.\HHHKD-PHHHH **1
MSA&([#->-R?$O7TFD4&WPK$#]W[U<*;GL3*2CN>RT5XQ_P +-U_UM_\ OW6Q
MX5\=:QJ_B.UL;HP^3)NW;4P>!FK=&25Q*HF>GT445B6%%%% !7G'Q9_X]-/_
M -]OY5Z/7G'Q9_X]-/\ ]]OY5I2^-$3^%GEM%%%=YSGM_P .O^1,M/\ >?\
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MPKSSQ6NW7I/=%->AUP7C%-NLJW]Z,5YV:*]#YGHY6[5_D0>%6V^(8!ZJX_\
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M[(3=M6=77G'Q9_X]-/\ ]]OY5W6D7<U_I5M=SQ"*2:,.4!Z9KA?BS_QZ:?\
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M<HTV[IE)S70['5OB#H>G0MY-P+N;'RI%R,^YKA](L+_Q[XG.H7RD6:,"Y_A
M'1!71Z9\*["!P^H74ESC_EF@V*?KWKN[2TM[&W2WM84BB085$& *GFC!>YN.
MSE\1*JA%"J % P .U><_%G_CTT__ 'V_E7H]8?B+PO9^)8X4NY9HQ$25\H@?
MS%13DHR394E=6/ J*]>_X55HW_/W>_\ ?2_X4?\ "JM&_P"?N]_[Z7_"NKV\
M#+V<C1^'7_(F6G^\_P#Z$:ZJL_1='@T+3(["V>1XHR2#(03R<]JT*Y).\FS9
M*R"BBBI&<K\1?^1+O/\ >3_T(5XA7T3K6D0:[I<MA</(D4A!)C(!X.>]<I_P
MJK1O^?N]_P"^E_PKHI5(QC9F4XMO0\AKT_X2?ZC5/]]/Y&K_ /PJK1O^?N]_
M[Z7_  K?\.>%K/PREPMI+-()R"WFD'&/3 %54JQE&R%&#3N;E9/B?_D6-2_Z
M]W_E6M5:_LX]0L)[.5F6.9"C%>H!KF3LS5['S=2UZ]_PJK1O^?N]_P"^E_PH
M_P"%5:-_S]WO_?2_X5V>W@8^SD8'PI_Y#5Y_UQ'\Z]:KG/#W@VP\-W4MQ:37
M#M(NTB4@C'X"NCKFJR4I71K!-*S(Y_\ CWE_W#_*OFR7_72?[Q_G7TLZAT93
MT88KAF^%>C,Q8W=[DG/WE_PJJ,U"]R9Q;V/(*Z?X>_\ ([6/TD_] -=O_P *
MJT;_ )^[W_OI?\*OZ-X TS0]5BU"WN+IY8LX61E(Y&.P]ZUE6BXM$J#3.LHH
MHKD-@HHHH 9)&LL;1R*&1@0RGH17C/B_P1<Z+<27=E&TNGL<C R8O8^WO7M-
M(RA@00"#U!JX3<'H3**D?,]:6@ZW<:!JL=];\X^5T/1U[BO7-7^'NAZH[2I$
MUI,W): X!^J]*Y:Z^$]TI/V74HG'_31"/Y5TJM"2LS+DDMCL-*\<:'J<*G[6
MEO*>L<QVD&M*;7](@3=)J5LJ^OF UY<WPNUL$@2VQ'KN-3V_PIU-V'GWEM&O
M? )-9.%/N7S3[&YXB^)5E;0/#I!^T7!&!*1\B>_O7F]]IM]%8PZI>!A]KD;:
M7^\_<M7JVB_#C2-,D6:YW7LR\CS!\@/^[_C6KXA\*V7B2*WCNI)HE@)*^40.
MOU%.-2$':(G&4MSP.BO7O^%5:-_S]WO_ 'TO^%'_  JK1O\ G[O?^^E_PK7V
M\"?9R-+X=_\ (EV7U?\ ]"-=36?HND0:'I<6GV[R/%'G!D()Y.>U:%<DG>39
MLE9!1114C"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#.UC28M5LS&V!*O,;]P?\ "O-[BWDM;AX)E*R(<$5ZS6#XDT0:C;^?  +F
M,<?[8]*\W'X/VJ]I#XE^)Z>7XSV4O9S^%_@<EI6I?95FM9B6M;A"KC^Z2."*
MS2,$C.<4$$$@C!'4&BO!E-N*B^A[T8)2<EU.S\%W6ZUGM2>4;</H:ZJO.O#%
MW]FUJ-2<+*"A_I7HM?0Y=4YZ"7;0^=S*GR5V^^H4445WG %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110!Q/BO1O(D^WP+^[<XD ['UKF*]9FA2XA>&10
MR.""#7FFK:<^EW[P-DIU1O45X&8X7V<O:1V?YGT&6XKVD?9RW7Y%*.1HI5D0
MX9&# ^XKU:TN%N[.&X3[LB!J\HKN?!UYYVFO;,?FA;CZ&C*ZO+4<'U%FM+FI
MJ:Z'24445[YX 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% #)&*1NPZ@$UY(WQ5UE78?9+'@X^ZW_P 57K4_^HD_W3_*OGO1
MHHY_$=E%*@>-[@!E/0C-;T8Q:=S.HVK6.J7XKZQN^:SLB/0!A_6M72_BM').
ML>IV'E(>#+"V<?4'_&NQ;PKH+*1_95K^"5P/CWP79Z78#5--4Q(KA98NHP>A
M'XTTZ<G:PFIK6YZA;7,-Y;I<6\BR1.,JRG@BH=6NWL-'O;R,*SP0/(H;H2%)
MYKAOA5J4DMI>:?(Q982'CSV!ZC\Z[+Q'_P BQJO_ %Z2_P#H)K*4>67*6G>-
MSB_"WQ U/7/$%O87%M:I%*&),8;/ SW->CUX9\//^1TL?]U__037N=76BHRL
MA4VVM2"^G:VL+B= "T<;. >F0,UYUX?^(FJZMKUK836UHL<S[6**V1^M>@:M
M_P @>]_ZX/\ R->(>"_^1QT[_KH?Y&G2BG%MBFVFCWNBBBL#01F"J23@ 9->
M5ZC\4M1AU&XBM+:T:W1RJ,X;) []:[#QUK(T?PS.4;$]Q^YB^IZG\!FO'8-$
MN)_#]UJZ@F&WD5",=<]3^''YUT48)J\C*<G>R/>]+U"/5-+MKV+&V9 V!V/<
M5<KSKX6ZQYUE<:5(WS0GS(P?[IZ_K7HM8SCRR:-(NZN%><^*O'^IZ%X@GT^W
MM[5XHPI#2!L\@'L:]&KP[XB_\CG>_P"ZG_H(K2C%2E9DU&TM#2_X6MK/_/I8
M_P#?+?\ Q56K?XLW8<?:-,A=>_ER%3^N:ZW0?#FC3Z!82RZ9;/(\"EF*<DXJ
M/6? &BZA:2"VMEM;@ ['CX&?<57-2O9HFT^YI:!XFT_Q';F2S<K(GWX7X9?_
M *U;5> :#>7/A[Q3 V2K1S>5*O9@3@BO?P01D=*SJPY7H5"5T<9XW\77WAJ>
MU2TA@D$RDMYH)Q@^Q%9?ACXBWFK:Y#8W\%M'',"JM&"#N[=353XL_P#'WIW^
MXW\ZXB6TN-,AT[4HR1YH\R-O1E/2MH4XN"ON1*34CZ)HJAHNI1ZOH]K?1GB:
M,,1Z'N/SJ_7*U8V,'Q;X@/AW17NXU1YRP2)'Z$FN"@^*6LRW$49M++#N%.%;
MN?K4?Q+U5M1\01:9 =R6P ('>1O\!C\ZYB[L?[,\0BS)R8I4!/OP3753IQY=
M=S&4G?0^A5.5!]12TB?<7Z4M<IL%>9^(/B3>Z?K=S9V$%K)#"VS?(&)+#KT-
M=MXEU9=%T"[O<CS%3;&#W<\"O$-/T>ZU:RU&^0DBU3S7_P!HD\_IDUO1@G=R
M,YR>R/;O#>M#7M#M[_"K(XQ(B]%8=16O7E/PLU?R;VXTN1OEE'F1Y_O#K7JU
M9U(\LK%1=U<****@H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:-G(%33MS78Y7MH<QX*\&P^)(KF>[DECAC(5#'CD]ZZS_A56C_\ /W=_F/\
M"NF\-Z,N@Z)!8@AG49D8?Q,>M:U5.K)RT8HP5M3SK4/A=81:?<26ES<M<(A9
M%8C!([=*X[P1JQT?Q/ 9#MBF/DR ^_\ ]>O=J\QU;X97=SK%S=6-U#%!)(9$
M1@<KGG'YU4*ETU-DRA9WB>FYSTI:K:?'<0Z?;Q73J\Z(%=EZ$CO5FN<U"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ K+U^P_M#2I449D3YT^HK4HJ*D%.+B^I=.;A)270\AKO/!]ZUQIC6[Y
M+0-@'_9/2JU]X.6>\>6WN!'&YW%"N<'VK<TK2H-)M?)B)9F.7<]6->3@L)6H
MUKRV_,];&XNC6HVCO^1?HHHKV3Q@HHHH **** "BBB@ HHHH **** "BBB@
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MH\[_ )Z.=S#Z>E;=35J\^B"$+:L****Q- HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>atha-20240221.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-02-22T16:00:51.5998+00:00 -->
<!-- Copyright (c) 2024 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://athira.com/20240221" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:atha="http://athira.com/20240221" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd" namespace="http://fasb.org/us-gaap/2023"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://athira.com/20240221/taxonomy/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://athira.com/20240221/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="atha-20240221.xsd#DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://athira.com/20240221/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140227311898064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Feb. 21, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 21,  2024<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Athira Pharma, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001620463<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Securities Act File Number</a></td>
<td class="text">001-39503<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">45-3368487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">18706 North Creek Parkway<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Bothell<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">WA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">98011<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">425<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">620-8501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ATHA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>8
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M>LT*-J]O=,Y"/G8@<357;]R9_/2#/_!^1?BZ%5\74Z\#N-CEO D.'SZ\^(Q
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( $6!5E@<.&7J/P$  #P"   /
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MDWM)J'7N0;#W\!J-'<V/'[?\ 5!+ P04    " !%@598)!Z;HJT   #X 0
M&@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4 -5"I
M0P5,75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K!LID
MR^SO *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1UW6E\
M./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6
M?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ 18%66&60>9(9 0
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M<',O87!P+GAM;%!+ 0(4 Q0    ( $6!5EC+T=KZ[@   "L"   1
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M96QS+RYR96QS4$L! A0#%     @ 18%66!PX9>H_ 0  / (   \
M     ( !E1   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( $6!5E@D'INB
MK0   /@!   :              "  0$2  !X;"]?<F5L<R]W;W)K8F]O:RYX
M;6PN<F5L<U!+ 0(4 Q0    ( $6!5EAED'F2&0$  ,\#   3
M  "  >82  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  # 4
$      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="atha-20240221.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://athira.com/20240221/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="atha-20240221.htm">atha-20240221.htm</File>
    <File>atha-20240221.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "atha-20240221.htm": {
   "nsprefix": "atha",
   "nsuri": "http://athira.com/20240221",
   "dts": {
    "inline": {
     "local": [
      "atha-20240221.htm"
     ]
    },
    "schema": {
     "local": [
      "atha-20240221.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://athira.com/20240221/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20240221.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "atha-20240221.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://athira.com/20240221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://athira.com/20240221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://athira.com/20240221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://athira.com/20240221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://athira.com/20240221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://athira.com/20240221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://athira.com/20240221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://athira.com/20240221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://athira.com/20240221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://athira.com/20240221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://athira.com/20240221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://athira.com/20240221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://athira.com/20240221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://athira.com/20240221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://athira.com/20240221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://athira.com/20240221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://athira.com/20240221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://athira.com/20240221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://athira.com/20240221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://athira.com/20240221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://athira.com/20240221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://athira.com/20240221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://athira.com/20240221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://athira.com/20240221/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0000950170-24-018764-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-018764-xbrl.zip
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M,=E&/0^+J QMKS8]U"]];X?$F K""0.-$0M[)>BK+!=UX8RJ=("M&"N;]?U
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MB?P5K\*=,L1%M2 \I1=L]4MT%L (X[RMF5F\82%W<1L:9 !"HD$A%!I9650
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M^^T@X\,//^RWNT4O^?#_4$L#!!0    ( $6!5EBJ-LO%"PD  &UI   1
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M! ROM/Q-(A,=:.T-#P##!,,%KL(7K0A?'E"APSFI-NWZ4L_N!7@,M/;KT1O
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M%)W AK6LR<I1;L!+7:W@:QJ"TY_4Q+=PA"=BW]41G F^.>3R?U!+ P04
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M:]GZ;PX(1]$[J,;Y1].1KP<>)0?"6A]O.B&_@0HY.%;0<=NFM.XWK?E-KN+
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M4[Y>H]I"I!>5(H9()\O*;$-#!P)_$CV(&*>Q3C&.NVISM3GP]75>IS%&'87
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MNXWXD8=@('!BM"34]=7#REO\O#@89L<[&XO (KBWP)S* V]G6MBBV?\'MQ*
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M$G!!8WKHV^ W75RBW!?!.Q#Z2Q*I=W";(D]'QKIO)$7\:K^+Z;R]O-7S_5C
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ML8\X>U,191I02L ;K(,PF&DL/TBYN")[\NGI^5/,+7!.HE)?X%&Q-KA]RH7
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MD.MQHZ-8!DU#%[2QN3W>Q\@?F.24'XWAC"JK:MPYD1R&UGC- \+@"5R6R[K
M>.-%O1 6'P,-^A:[_,WWX.,>?#] [].CJX6#'DU1L>;7FCD/!LRXC0ST^T)G
M( Z?8 5BV:G)8+\DT,G+@OQP/0%^*UI?>W\>1%O ^/-2JIQ.Q'\@'S%&JJ;9
M(D/NJ466Z']B@M=#W\#26T[ARJ/0.J=JN<KF_+'+?)%&*(36. (./"<4KQ+Y
M:D#+A6)PR4<4*;I2L$-HQ9,[0VYI*49$KB&R=6*;=9[EI<Y>Z,^L*%F;<KY8
MNPKA&.ZP%?^QGS&)W_)BKC*Z5IYCXGURFW.PU>AV+U 3L*CQX#+[6TX+WOGE
MYP F KGNF2(SQV=*&\A -Z0@[!A\6LO-HV/[S:TQ^+L@7OA\Q14Q1;^,%HFB
MT,<JI^VOCUE#([M*N_%MFN"-<&ZE<WCOLD7XJ9\6X0C][> <W^JF'W+P#I;R
MM&8/ 2\%BPRVU5HV"5W$@HMEMWO5V'#L5Z^0!Q&W'NQ([6*T/-@- [0EU%FC
M?H[+WDVS@T=V#4WV3NA8'%6761'3\40AF1==SM2>%'DGZK!WL@S[*Z_"[ELZ
M\&L[4SF^)(<&AT:+9%7B/1&,.=@6=$7 V%YZO@O=< ^2@?$+5P:OZP2B[!76
M/I-C!W"9AFNAD.]@(*^<)S,PX.O024)^8'@,7.RD!=<P8"GR"\L543]9RF@P
M;>2C61?)#36H<.[V5PR,%>[=DH*L\IQ=]J_^W$__:I)\= IKRAV>H&=]!92>
M>G$9NF]-,%JR53>XDQ\=PS 8DKL )Y>NQP(W3#CP4B4?U$HGO.Q5EIS@-)M3
M"*V*.\+UG)\J/B6Z!2:(<P>!A\WW=)+?X0MM&1U4^06E0]D1[G.5JKZ$GRKH
M4887_1X4JO*PU8LJ6V) V(0/W1@?GB1_HG TW$,0T  7$3I2[*=MH)&#@%YH
MOR,!W%559C 7,7TVKRMXT3)C,ODX.L@&E),05;&8#E4Y11?YC&/UN#(L=J-U
M8?XFJF1CTYU#&!Y]0X0;WZR*#GX;'PX';N\&'++$2D#IHX[<8ULOU8*"(CAP
MC>FVL2,G9PAM_89H[S%17JFED."K,,EIVWVE?\E);@=(0", >QA#6C9\%#P(
M!S ;M#\:'A"*SYE.=O6*%U#CU_:A\R)#KGW)&M%Z<H+4&1D:C'C1ZL*.FP5R
MP8H;!K=-\):J6B@S>-TY(?QLLE 6]"-N%N;!G(AV<Y)X\7!ZJF'"FU;I,BDY
MA(XA.XP.R')(BK@A&+BAN0=^WRBZ!4W', "FJZ2 26=&3>QK$!V O5C@SKI6
MBW7_;6"'Y[)5 YAID[4$#[CLR#UAD4&P(/!+F+I0'V=*I$*295[3V8K%M)+W
MTC:!_FYW96/E'92#+DV+\*C&P%!SY1Z I5K"25U*8LB*>HDL!\TDG.6PF4HY
M[$U,&:[#E5MH$$Q4FPTG!X$7]\:]Z%ETK+U Z -9=-HL<<M>_Y2MSM\OP9D
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M,MA[-JTS"RT]N ;?AI[-[H@W%?Y5(548I@<7I,BOBDR(0.:MYSZF"=B+%G8
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M2/69=TQAI4/3TCK(CJ%3GJR@CY301N0-U_)LI-%J@W!U-4(@+Z4IHFV0;S>
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M$Q9CMQ5B43*?:ZH<<T7^%<=JIY=F-GC&A=-&+I 6)H?$L3!GS9JW36*[%OL
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MUV3L)DX@EZ=2D;8?9A V- SV_C3CN#HAF7VQE]3U/.%01EY\!@'F1)'O%OO
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ML80PNW_X70_(G:SXU?J-# BZRP&0F3/ 0R&VDOOY_'^\X)/*W0ZMQT8(Y0Q
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MG[;"%T(O6O+A_8)>] 0]=C?@P5__A"3B__U__OJGRVJY^.__#U!+ P04
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MN )@( )]'0ZE#]**1AZA8YW--HQQ  P1^[!X0"&0TVDA^7JL+F/<'Q38?.%
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M!Q,0+3]F&DJ;G!46\DN=R;3._H[W#-B6(&JB-"74Y+2<GQM-B' TXC]@=*:
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M]IU.D6Y[EM U>^7G3V7>OXE]$ZC 9U\\ZE*"@6E4OF99Q94  VY=-Z 27D>
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M4$L! A0#%     @ 18%66*HVR\4+"0  ;6D  !$              ( !]Q<
M &%T:&$M,C R-# R,C$N>'-D4$L! A0#%     @ 18%66-VW9ZLMM   XT0&
M  \              ( !,2$  &%T:&$M97@Q,%\Q+FAT;5!+ 0(4 Q0    (
M $6!5EA]99:_HB8  %X^ @ /              "  8O5  !A=&AA+65X.3E?
;,2YH=&U02P4&      0 ! #X    6OP

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>atha-20240221_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="atha-20240221.xsd" xlink:type="simple"/>
    <context id="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001620463</identifier>
        </entity>
        <period>
            <startDate>2024-02-21</startDate>
            <endDate>2024-02-21</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8"
      id="F_bc348e5a-23b4-4d14-9b18-3de0e63e34b1">0001620463</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8"
      id="F_ed3073ed-fbb1-42ee-bd4b-1f7f0cf8a941">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8"
      id="F_0e6af6f7-8ffc-479b-bea7-f0eef1916554">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8"
      id="F_a7c30f43-4619-42e9-98dd-89a1dbbf343e">2024-02-21</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8"
      id="F_b33b3df9-7198-4601-ab97-50f613c3ea95">Athira Pharma, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8"
      id="F_97c6436e-8a3a-4135-b6f4-b86aae3b15a1">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8"
      id="F_84f450fb-b9c2-4d75-bb9e-1457628645e8">001-39503</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8"
      id="F_f76b8a7d-4972-4a36-a4a4-859d23773d7f">45-3368487</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8"
      id="F_09782a93-8e97-44b6-9c54-38c667647ed3">18706 North Creek Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8"
      id="F_b897400c-cdc8-41dd-8693-f74235025ba8">Suite 104</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8"
      id="F_95179633-6c7a-4313-94c6-dd380e78b6ce">Bothell</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8"
      id="F_85772bb9-3352-4a1e-bfa8-fad543a4ad86">WA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8"
      id="F_0a1552fe-8eaf-418c-961a-2cd4cdf9b501">98011</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8"
      id="F_2903e6a9-ba5a-47d8-b5d1-9fb82249ab36">425</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8"
      id="F_0b77acdb-5c9a-4bec-87c6-94e511e42c56">620-8501</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8"
      id="F_581b6222-14bc-448e-9a9b-88d29a4e0048">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8"
      id="F_4090156c-fe1b-4496-8ff4-bbf4ae9d768b">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8"
      id="F_347c9ccc-5e05-4c47-af51-3eaaf886afef">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8"
      id="F_6c81df5e-859f-4626-86fc-0f61386d7a0f">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8"
      id="F_497fc471-dbad-493c-ba6d-f91278f30cc0">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8"
      id="F_9beb45f3-0f04-47d8-812b-9a825b3e6fb5">ATHA</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8"
      id="F_5469c7f0-cdc4-4da6-aae3-42818423cb87">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8"
      id="F_f7d1e54e-fa92-4213-bbaf-019470183ed0">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_aaab0fff-78c6-4d75-bf63-1fa3a43e97f8"
      id="F_65baee7c-e5f5-4ea0-8cbd-bd8332dc3918">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
